Evaluation of the efficacy of extracorporeal shock wave therapy (ESWT) on osteoarthritis and post-ESWT analgesia in animal models by Dahlberg, Jessica Ann
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
1-1-2006
Evaluation of the efficacy of extracorporeal shock
wave therapy (ESWT) on osteoarthritis and post-
ESWT analgesia in animal models
Jessica Ann Dahlberg
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Dahlberg, Jessica Ann, "Evaluation of the efficacy of extracorporeal shock wave therapy (ESWT) on osteoarthritis and post-ESWT
analgesia in animal models" (2006). Retrospective Theses and Dissertations. 17528.
https://lib.dr.iastate.edu/rtd/17528
Evaluation of the efficacy of extracorporeal shock wave therapy (ESWT) on 
osteoarthritis and post-ESWT analgesia in animal models 
by 
Jessica Ann Dahlberg 
A thesis submitted to the graduate faculty 
In partial fulfillment of the requirements for the degree of 
MASTER OF SCIENCE 
Major: Veterinary Clinical Sciences (Veterinary Surgery) 
Program of Study Committee: 
Scott R. McClure, Major Professor 
Michael Conzemius 
Richard Evans 
Iowa State University 
Ames, Iowa 
2006 
Copyright© Jessica Ann Dahlberg. All rights reserved. 
ii 
Graduate College 
Iowa State University 
This is to certify that the master's thesis of 
Jessica Ann Dahlberg 
has met the thesis requirements of Iowa State University 
Signatures have been_ redacted for privacy 
lll 
TABLE OF CONTENTS 
CHAPTERl.GENERALINTRODUCTION 
Thesis Organization 
Introduction 
CHAPTER 2. LITERATURE REVIEW 
Pressure wave generation and focusing 
In vitro 
In vivo 
Bone 
Ligamentff endons 
Joints 
Other applications 
Analgesia 
Complications 
References 
I 
1 
1 
1 
3 
3 
5 
7 
7 
14 
24 
27 
29 
34 
35 
CHAPTER 3. THE EVALUATION OF EXTRACORPOREAL SHOCK WA VE 
THERAPY IN NATURALLY OCCURRING OSTEOARTHRITIS OF THE STIFLE 
JOINT IN DOGS 49 
Summary 49 
Introduction 50 
Materials and Methods 51 
Results 54 
Discussion 55 
Footnotes / References 58 
Legends of Tables and Figures 61 
Tables and Figures 62 
IV 
TABLE OF CONTENTS (CONTINUED) 
CHAPTER 4. FORCE PLATE EVALUATION OF ANALGESIA FROM FOCUSED 
EXTRA CORPOREAL SHOCK WA VE THERAPY IN UNILATERAL FORELIMB 
LAMENESS 65 
Summary 
Introduction 
Materials and Methods 
Results 
Discussion 
Footnotes 
References 
Legend of Figures 
Figures 
CHAPTER 5. GENERAL CONCLUSIONS 
ACKNOWLEGEMENTS 
65 
66 
67 
69 
70 
72 
73 
75 
76 
77 
79 
1 
CHAPTERl.GENERALINTRODUCTION 
Thesis Organization 
The literature review in Chapter 2 is intended to offer the reader a greater 
understanding and a comprehensive summary of the current knowledge that motivated this 
manuscript. The primary objectives of this thesis are included in two published manuscripts 
that are included in Chapters 3 and 4. The first publication is titled "The evaluation of 
extracorporeal shock wave therapy in naturally occurring osteoarthritis of the stifle joint in 
dogs". The second paper is titled, "Force plate evaluation of analgesia from focused 
extracorporeal shock wave therapy in unilateral forelimb lameness". Each study contains a 
separate summary, introduction, materials and methods, results, discussion, references, 
tables, and figures. The general conclusion in Chapter 5 discusses the results of each study 
and mentions the contribution they have made to the existing data involving extracorporeal 
shock wave therapy. 
Introduction 
Therapeutic use of extracorporeal shock wave therapy (ESWT) was first reported for 
the treatment of uroliths in humans in the 1970' s and has been used in human orthopedics for 
over 10 years (1,2). ESWT has had promising results treating a wide variety of 
musculoskeletal diseases resulting in bone remodeling, neovascularization of bone-tendon 
interfaces, and orthopedic pain relief (2, 3). ESWT has been applied to musculoskeletal 
diseases in animals in the United States for over 7 years (4). Although, ESWT has been used 
extensively in human and veterinary medicine, questions regarding efficacy and mechanism 
of action remain. 
Osteoarthritis is a significant cause of lameness in humans and animals (5, 6). 
Interestingly, studies evaluating the ESWT for osteoarthritis are lacking in literature and 
further trials are necessary. In Chapter 3, we have evaluated the effect of ESWT on naturally 
occurring osteoarthritis in the stifle joints of dogs. 
2 
Analgesia has recently been identified as a potential side effect of ESWT. There are 
no studies that objectively evaluate analgesia following ESWT. In Chapter 4, we have 
evaluated the analgesic effect of ESWT in horses. 
There remains much to be learned about ESWT, as it becomes a widely accepted 
treatment for musculoskeletal disorders. This manuscript explores the efficacy ofESWT on 
osteoarthritis and characterizes post treatment analgesia effects. 
3 
CHAPTER 2. LITERATURE REVIEW 
Pressure wave generation and focusing 
Shock waves are acoustic pressure pulses that may reach very high pressures up to 
1000 times atmospheric pressure (100 MPa). These pulses reach maximum pressure in 
nanoseconds while the entire pulse lasts 5-6 microseconds (7). Shock waves used in clinical 
situations are single-pulse mechanical pressure waves focused on target tissue (8, 9). The 
pulses are delivered relatively slowly with up to 4 pulses per second. 
To date, three types of focused shock wave generators have been used to perform 
these functions (8, 9). All generators use a fluid media in which the shock wave is generated. 
With electrohydraulic devices, a spark is discharged through a converting medium and 
generates the pressure or shock wave, which is focused by a parabolic reflector. With 
electromagnetic shock wave devices, electric current induce magnetic fields that cause 
membranes to repel each other, resulting in compression of the converting medium and 
ultimately, focused shock waves. Using piezoelectric shock wave devices, focused shock 
waves result from oscillating quartz crystals in an electrical field. As a pressure wave moves 
through tissue, there is compression in front of and tension behind the wave. As the wave 
travels, a negative component on the trailing edge creates tension. This can create cavitation 
bubbles at interfaces of free gas or solid particles ( 10). The moving bubbles collapse 
asymmetrically creating a water jet onto the surface (11). A surface pit, created by the 
collapse of the bubble, has the same diameter as the water jet and is believed to disrupt the 
contacted tissue (12). Studies have shown that the interaction of lithotripter-generated shock 
waves with gas bubbles generate water jets with speeds up to 700 m/sec or nearly the spe~d 
of a rifle bullet (13). 
Once generated, shock waves are then focused by an ellipsoid or lens and directed at 
a treatment site in the body. If all material parameters are the same, the smaller the focus of 
the shock wave, the higher the positive pressure targeted at a smaller area. Shock waves may 
be dispersed over a larger area by increasing the focus size. The focusing devices mentioned 
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previously concentrate acoustic (mechanical) energy into focal areas and thus, increase 
desired tissue changes at the target area while avoiding effects in surrounding tissues (8). 
This concentrated shock wave energy per unit area is referred to as Energy Flux 
Density (EFD) measured in millijoules per square millimeter (mJ/mm2). The size of the 
ellipsoid and strength of the initiating current determine the EFD produced by the source (8). 
Total energy of therapeutic shock waves also depends on the number of pulses delivered to 
the target tissue (14). Human ESWT treatment typically uses 0.0001 to 0.6 mJ/mm2 and 
EFD and pulse parameters are similar in veterinary ESWT (15, 16). Energy flux densities up 
to 0.89 mJ/mm2 have been used in horses (17). 
Kinetic energy is released when shock waves encounter a difference in acoustic 
impedance between 2 tissues such as muscle and bone. Shock waves can travel through 
tissues of similar acoustic impedance without losing a significant amount of energy. The 
acoustic impedance of fat, muscle, and water are similar (1380, 1650-1740, 1480 x 103 Ns/m3 
respectively). Conversely, there is a large difference in the acoustic impedance of air ( 429), 
lung tissue (260-480), bone (3200-7400), and uroliths (5600-14,400 x 103 Ns/m3) (8). Shock 
waves are reflected, refracted, or absorbed at the interface of 2 tissues with unlike acoustic 
impedances and kinetic energy is released. Then, through unknown mechanisms, the shock 
waves cause tissue alterations and responses that have been useful in clinical applications. 
Radial Pressure Wave Therapy (RPWT) 
RPWT differs from ESWT in that radial pressure waves have different pressure 
profiles than shock waves. Extracorporeal shock waves are generated in fluid by the 
conversion of electricity into fast-moving high pressure waves. Conversely, radial pressure 
waves are created by discharges of compressed air that cause acceleration and collision of a 
projectile with a probe in the hand piece (8). Mechanical concussion generates waves of 
pressure, which decline in an inverse square proportion to the distance from the source. 
Maximum pressures of radial pressure waves are 100 times lower than ESWT and pulse 
durations are 1000 times longer. In contrast to ESWT, which delivers energy to deeper 
tissues, RPWT delivers maximal energy to the skin surface. 
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Cleveland et al compared ESWT and RPWT and found that the ESWT device 
produced cavitation, which lasted for 110 to 140 µs while the RPWT generator produced no 
detectable cavitation (18). This study highlights the physical differences of RPWT and 
ESWT. Much less information on RPWT than ESWT exists in literature. 
ESWT effects in vitro 
Cell membrane alteration 
Low energy shock waves (0.12 mJ/mm2) applied to cell cultures resulted in alteration 
of cell membranes (19). Gambihler et al thought that the cavitation effect of shock waves 
causes disruption of cell membranes and thus, increased permeability (20). The study applied 
1000 pulses at 25 kV to a suspension of cells while a control cell suspension received sham 
treatment. After treatment, 15% of the ESWT cells remained undisturbed while 100% in 
sham treated controls remained undisturbed. Numerous researchers have utilized this shock 
wave-induced increase in cell membrane permeability in cellular studies. This transient 
increase in permeability allows for the passage of macromolecules such as oligonucleotides 
and small proteins into the cell cytoplasm (19). Gene therapy and photodynamic tumor 
treatment has utilized shock wave-induced fluorescein dye transfer into cells. Other 
experiments have delivered ribosome-inactivating proteins into cells, thereby, reducing drug 
concentration used to alter cell proliferation by up to 40,000 times (21). The enhanced 
cellular permeability caused by ESWT has also increased the effects of chemotherapy by 
aiding in chemical transfer into cells to decrease tumor perfusion (22). 
Osteogenesis 
Studies performed in vitro on bone marrow stromal cells have resulted in enhanced 
stromal cell growth, production of Transforming Growth Factor-beta l(TGF-131), and 
differentiation of stromal cells into osteogenic cells (23). TGF-131 is a growth factor with 
chemotactic and mitogenic effect on osteoblastic cells. Shock wave stimulation of TGF-131 is 
dose related with no effect at low levels and adverse effects such as stromal and bone cell 
damage at excessive levels. Increases in concentrations of osteogenic TGF-Bl occur as 
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superoxide radicals, such as nitric oxide, increase. Studies suggest that nitric oxide may be 
important secondary messenger in biologic fracture repair (24). Shock waves generate free 
radicals and, therefore, may play an important role in biological processes such as fracture 
repair. Another investigation involving substance P, a neurokinin involved in osteoblast 
proliferation, had higher levels in shock wave treated rabbit femurs (25). Additionally, 
studies using cell cultures found that ESWT increases both osteoprogenitor cell division and 
bone morphogenetic protein concentration. Bone morphogens proteins are growth factors 
belonging to the TGF-~ super family involved in new bone and cartilage formation (2_3, 26). 
The osteoblastic and cell-altering capabilities shock waves have displayed in vitro 
have resulted in further in vivo research and applications of shock waves on musculoskeletal 
disorders such as delayed and nonunion fractures, periarticular, and intra-articular diseases. 
Multiple ESWT studies have described ESWT to stimulate remodeling of bone, increase 
blood flow to bone-tendon interfaces, stimulate healing of ligaments, and alleviate pain 
associated with musculoskeletal disorders (3). ESWT has become the preferred treatment for 
hypertrophic pseudoarthrosis in humans and is considered a superior noninvasive treatment 
for calcific tendonitis, tendinopathies, and periarthritis. 
Bone microdamage 
In 2004, Da Costa Gomez evaluated the effect ofESWT and RPWT in vitro on 
microcracks in equine bone (27). Mid-diaphyseal third metacarpals and third metatarsals 
were collected from 11 Thoroughbred racehorses with a unilateral catastrophic injury from 5 
non-racing horses. ESWT (9,000 pulses 0.15 mJ/mm2, 4 Hz) and RPWT (9,000 shock 
waves, 0.175 mJ/mm2, 4 Hz) treatments were randomized to the proximal and distal 
segments of the long bones. The middle segment was used as a treatment control for pre-
existing microcracks. After ESWT, bone specimens were stained and sectioned. Microcrack 
density and microcrack surface density were increased after focused ESWT. Microcrack 
length was increased after RPWT. These preliminary data suggest that ESWT and RPWT 
have the potential to increase bone microcracking in equine distal limb bone in vivo. 
However, contrasting results were found in another microcrack study (28). Eight 
dorsal cortical bone specimens were treated with 2000 pulses of ESWT at 0.15 mJ/mm2 and 
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8 specimens were treated with 2000 pulses ofRPWT at 0.16 mJ/mm2. The ultrasound 
velocity was determined in each bone specimen before and after each of the 4, 500 pulse 
treatments. The research team found that velocity, and therefore the modulus elasticity, was 
not affected by ESWT or RPWT and there was no formation of microcracks. 
ESWT effects in vivo 
A major benefit ofESWT use in clinical applications since its inaugural use with 
uroliths has been to avoid surgery. This advantage continues to validate and motivate the use 
of ESWT in various clinical applications today. The success of ESWT in in vitro studies has 
prompted extensive research from numerous in vivo trials to clinical application in human 
and veterinary hospitals. The ensuing review will discuss in vivo explorations and clinical 
applications ofESWT on musculoskeletal disorders including bone, tendon, ligament, and 
joint diseases. Additional clinical applications and potential complications are also 
discussed. 
BONE - RESEARCH 
Osteogenesis 
ESWT has been shown to induce osteogenesis in laboratory animals (29, 30, 31). 
First, the focused shock waves produce micro fractures of trabecular bone resulting in release 
of osteoinductive growth fractures. Next, a "fracture hematoma" forms and 
neovascularization ensues attracting osteoprogenitor cells. Finally, osteoblasts proliferate 
and bone formation occurs. Delius et al performed an in vivo study applying very high-
energy shock waves (1500 pulses at 27.5kV) to rabbit bone (29). Initially, bone disruption 
was evident by periosteal detachment and subperiosteal hemorrhaging. However, during the 
weeks following ESWT, intense apposition of new cortical bone lead to considerable cortical 
thickening. 
In vivo osteogenic qualities of shock wave therapy were first detected in studies with 
rabbits. One thousand five hundred shockwaves at 27.5 kV were applied to the normal 
femurs of 19 rabbits divided into 5 groups. Periosteal elevation, cancellous bone disruption, 
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and osteonecrosis occurred following the shock wave treatment (29). Studies in rabbit radius 
defect models found that treated bones had greater callus formation than non-treated bones 
(32, 33). In bilateral 1 cm radius defects, ESWT was applied via fluoroscopy to 1 forelimb 
on days 7, 14, and 21 while the other forelimb served as a control. After 6 and 12 weeks, the 
subjects were sacrificed and the calluses were examined. The average callus area in the 
ESWT-treated radial defect was greater in both the 6 and 12-week groups and statistically 
significant in the 12-week group (p < 0.05). Uslu et al concluded that ESWT has a 
disorganizing and dispersing rather than a direct osteoinductive effect on callus formation 
(33). In 1991, Ekkercamp et al performed ESWT in vivo on sheep models and used 
fluorescent microscopy to confirm dose dependent osteogenesis (34). Tischer et al 
investigated the ability of shock waves of varying EFDs to cause osteogenesis outside of the 
focus zone (35). Eighteen adult Chinchilla-Bastard rabbits were assigned into 3 groups and 1 
distal femur of each animal was treated with focused shock waves. Two EFDs (1.2 mJ/mm2, 
0.9 mJ/mm2) and a sham treatment group were used. New periosteal bone formation outside 
the shock wave focus was significantly increased in rabbits in the group treated with 1.2 
mJ/mm2 compared to the 0.9 mJ/mm2group (p = 0.007) or the sham group (p = 0.001). 
The scenario of bone damage resulting from high-energy shock waves appears to be 
applicable only to laboratory animals and has not been reported in dogs or humans. The 
mechanism of bone stimulation seen in large animals is likely due to other mechanisms (28). 
Fracture healing 
One of first studies on fracture healing was performed in rats (36). Mid-diaphyseal 
humeral fractures were created in 40 rats. Thirteen rats were treated with 100 pulses (14 kV), 
13 subjects were treated with 100 pulses (18 kV), and 14 rats served as controls. ESWT was 
performed on days 2, 5, 9, 14, and 19. Measuring breaking strength, the fracture site of the 
treated bones were 18% (14 kV) and 30% (18 kV) stronger than the control bones. 
ESWT has had beneficial effects on in-vivo non-union canine models (37). Johannes 
et al performed radial ostectomies on 10 beagles, which resulted in hypertrophic non-unions. 
Twelve weeks later, 4,000 pulses (0.54 mJ/mm2) were delivered to the ostectomy site of 5 
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dogs. Four of 5 treated dogs experienced osseous union in 12 weeks after treatment and only 
1 of 5 control dogs developed osseous union. 
The effect of shock wave therapy has been studied on acute fractures fixed internally 
with orthopedic implants (38). Bilateral tibial fractures with 3-mm gaps were created in 8 
adult dogs and the metallic plates and screws were applied. Two thousand pulses (14 kV) 
were delivered to the fractures while the contralateral limbs served as controls. Serial 
radiographic examinations evaluating callus formation were taken at 1, 4, 8, and 12 weeks. 
Tissue histology was examined at 12 weeks. Radiographically, there was no statistically 
significant difference in the amount of callus formation between the treated and the control 
groups until 12 weeks after ESWT when the treated dogs showed significantly more callus 
formations than in the control group. Histologically, there was significantly more dense 
cortical bone formation in the treated group at 12 weeks. The researchers did not describe 
any disturbance to the bone plate or screws. 
Orthopedic implants 
A potential application of shock waves is to loosen bone cement 
(polymethylmethacrylate) used for prosthesis placement (39). Cement extraction contributes 
to morbidity associated with arthroplasty revisions. Using the same mechanism to fracture 
uroliths, ESWT may break apart the implant material and facilitate removal of the prosthesis. 
Weinstein et al suggest that ESWT may be useful adjunct in revision surgery necessitating 
extraction of polymethylmethacrylate before replacement of endoprosthesis. Shock waves 
were focused at the bone-cement interface in 1 femur of 6 pairs of canine femurs with 
femoral stem implants. The other femur served as a control. The results found that the 
ESWT-treated femurs had significantly less shear strength than the control femurs (P < 
0.003). Additionally, microfractures were seen at the bone-cement interface. Stranne et al 
subjected canine femurs to either manual cement extraction or ESWT followed by manual 
cement extraction ( 40). The contralateral femurs served as controls. No statistical 
significance was demonstrated between the 2 groups in relation to mechanical properties 
(torque, angle, or energy capacity). ESWT exposure had a minimal and insignificant effect 
on bone strength at bone-cement interfaces. The inconsistent effects of ESWT on loosening 
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cemented orthopedic implants suggest that more research is warranted to define the role of 
ESWT in revision arthroplasty. 
BONE - HUMAN CLINICAL APPLICATIONS 
Non-unionslpseudoarthrosis 
Osteosynthesis and bone grafting has been the gold standard for treatment of delayed 
or non-union fractures and pseudoarthrosis in humans. However, the low risk and non-
invasive nature of high-energy shock wave therapy has proven to be a valid alternative to 
invasive surgical treatments of these diseases in humans (2, 3, 14, 16, 30, 31, 37, 41, 42, 43). 
Over the last decade, ESWT has become the preferred treatment for non-unions in humans 
according to the largest study to date (44). Seventy-six to 85% of treated non-unions in 
people have undergone fracture healing ( 45, 46). Encouraging results from ESWT occur 
with fracture gaps less than 5mm, whereas fracture gaps greater than 5mm do not respond 
favorably to ESWT (44). ESWT has proven to be successful on long bone diaphyseal 
pseudoarthrosis (31 ). Two thousand pulses (18 kV) were applied to diaphyseal 
pseudoarthrosis sites. Within 6 weeks, a callus formation was manually detected in the non-
union soft tissue. The callus transformed into bony union in 3 of the 4 cases. 
Human non-unions respond differently to ESWT depending on their location. Shaden 
et al conducted a study using ESWT to treat various bone fractures or delayed bony unions in 
115 patients (42). The ESWT treatment lasted 20 to 60 minutes and the amount ofEFD and 
number of pulses applied depended on the fracture site. Scaphoid fractures received an EFD 
of 0.25 to 0.35 mm/mJ2 and 1000 to 2500 pulses. Tibia or femur fractures received an EFD 
of 0.4 mm/mJ2 and 12,000 pulses. Eighty-seven (75.7%) of the patients achieved union. 
Those patients who failed to achieve union may not have healed due to defects greater than 5 
mm or inadequate immobilization. 
Another ESWT study was performed on 43 patients with pseudoarthrosis persisting 
for 9 months after trauma or selective osteotomies (47). All patients received a single session 
of 3000 impulses at an EFD of 0.6 mJ/mm2 under regional anesthesia. Radiographs and bone 
scintigraphy were performed from 8 weeks to 9 months after ESWT. Thirty-one of 43 
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(72.1 % ) patients developed cortical bridging at their pseudoarthrosis site at approximately 4 
months after ESWT. Twenty-five of 31 (80.6%) of the successfully treated patients showed 
active bone growth (positive scintigraphy) while 4 of the 12 (33.3%) unsuccessfully treated 
patients showed positive scintigraphy. Twenty-nine of the 35 (82.9%) patients with a 
positive bone scintigraphy displayed evidence of bony healing compared to 2 of 8 (25%) 
patients with a negative bone scintigraphy. 
Non-union fractures with hypertrophic biological activity have benefited from ESWT 
more than atrophic non-unions ( 48). Unstable, avascular, or hypoplastic non-unions in 
humans do not benefit from shock wave therapy ( 42). In a 2000 study in humans, 100% of 
hypertrophic non-unions developed bony union while only 34.6% of atrophic non-unions 
achieved bony union after ESWT ( 45). Duration of non-union healing also influences the 
onset of bony union regeneration. A recent human study found that those with non-unions 
lasting 6 months or less experienced a decreased fracture gap by 3 months post ESWT. 
Those subjects with non-union fractures lasting 9 months or more experienced a decrease in 
fracture gap by 4 months post ESWT. Those with shorter duration of non-union before 
ESWT also endured less pain and more callous formation post ESWT (42). 
Femoral head osteonecrosis 
EWST has been investigated as a potential non-invasive alternative for osteonecrosis 
of the femoral head (49, 50). Twenty-two patients with femoral head necrosis confirmed 
with MRI results were treated with ESWT and evaluated 1 year post treatment (50). Visual 
Analog Scores (VAS) evaluating pain decreased from 8.5 before treatment to 1.2 one year 
after ESWT. Additionally, the Harris hip score increased from 43.3 to 92 points. The Harris 
Hip Score is a subjective analysis of degree of pain during and extent of ability to move the 
coxofemoral joint. Furthermore, patients who responded favorably to ESWT had an absence 
of a distinct zone of sclerosis around the necrotic area remaining after treatment. The study 
suggests that ESWT is valuable modality for the treatment of femoral head necrosis in the 
early stages of the disease process. 
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BONE - VETERINARY CLINICAL APPLICATIONS 
Non delayed-union fractures I pseudoarthrosis 
As in human medicine, ESWT is more effective on non-union fractures with 
hypertrophic biological activity than on atrophic non-unions ( 48). Similarly, unstable, 
avascular, or hypoplastic non-unions do not benefit from ESWT (37, 43). The osteogenic 
and neovascular properties ofESWT may be useful for fractures with delayed healing such 
as those seen in the ulna or distal radius of toy breeds, multiple fractures, open fractures, 
fractures in older animals, and fractures in systemically ill animals (3, 51, 52, 53). 
A case study utilized ESWT in horses with distal phalanx fractures refractory to 
conservative treatments such as nonsteroidal anti-inflammatory drugs and corrective shoeing 
(54). McClure performed 3 treatments at 2 week intervals targeting shock waves (EFD 0.15 
mJ/mm2) through the frog. A bar shoe was maintained throughout the treatments. In this 
study, the horse treated with ESWT for a distal phalanx fracture was clinically sound and 
returned to race training 10 weeks after the first ESWT treatment. 
Dorsal metacarpal disease 
Bucked shins result from repetitive loading and consequent bone remodeling in the 
dorsal cortex of the third metacarpal bone. ESWT has shown to increase the number of 
activated osteons from the periosteum to the endosteum of the third metacarpal bone (55). A 
separate study suggests that ESWT may be a useful adjunctive therapy in addition to training 
modification in horses suffering from dorsal metacarpal disease. Fifty thoroughbred 
racehorses with clinically or radio graphically evident dorsal metacarpal disease were treated 
with RPWT and a modified training program (56). After completion of treatment, 40 of the 
50 horses returned to racing without recurrence of lameness. Twenty of the 50 horses with a 
single oblique dorsal cortical stress fracture returned to racing in a mean time of 5 months 
after the last ESWT treatment (56). A separate study had similar results. Eight hundred 
pulses at 0.14 mJ/mm2 were delivered to the dorsal aspect of the third metacarpal bone at 1 to 
2 week intervals for 3 treatments (54). A cycle of 1 week of walking and 2 weeks of training 
was repeated twice. When treated early in disease with this ESWT protocol, the study 
showed that most horses return to training. 
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Incomplete/stress fractures 
Horses with stress fractures in the humerus, tibia, or third metacarpal bone may be 
treated with ESWT (57, 58). Scheuch, et al found promising results 90 days after ESWT on 
metacarpal stress fractures in 10 horses (57). Six horses showed clinical and radiographic 
resolution of their stress fractures and 2 horses showed signs of healing in 120 days. The 2 
other horses were retired. Analgesic effects offered by ESWT when applied to stress 
fractures may lead horses to returning to work before stress fractures are actually healed. 
Therefore, radiography and scintigraphy should be used to evaluate stress fracture response 
to ESWT before returning a treated horse to work (58). 
Proximal splint bone fractures 
A recent study used ESWT on a total of 7 horses; 4 non-infected and 3 infected 
proximal splint bones (Weinberger, T unpublished data, 2003). The horses with infected 
fractures were given local and systemic antibiotics, their fracture sites were curetted and 
lavaged, and the skin defect was allowed to heal before ESWT was performed. All 7 horses 
received 3 treatments at 10 to 14 day intervals. Depending on the size of the lesion, either 
the 5 mm and 20 mm or the 20 mm and 35 mm probes were used to deliver a total of 600 to 
900 pulses to the fracture sites at an EFD of 0.15 mJ/mm2• Horses with closed fractures 
returned to training 10 to 12 weeks after the fracture while the horses with open fractures 
took 1 to 6 weeks longer to become sound. 
Navicular syndrome 
ESWT has been evaluated as a treatment for navicular syndrome in horses (58). In a 
recent study, 16 horses with navicular syndrome were administered 1000 pulses (0.89 
mJ/mm2) through the frog and 1000 pulses between the heel bulbs of the affected feet with 
while under general anesthesia. Blinded evaluators subjectively graded the lameness in each 
horse before and 6 months after ESWT. On a lameness scale of Oto 5, the average lameness 
grade was 1.8 when trotted in a straight line on a hard surface before treatment. When the 
affected limb was inside while trotting in a circle, the average lameness grade pre-treatment 
was 2.6 (0 to 4 scale). After treatment, 9 of 16 (56%) horses improved and the mean 
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lameness grade decreased to 0.7 and 0.9 while trotting in a straight line and in a circle, 
respectively. Radiographs were performed before ESWT. It was proposed that horses with 
radio graphically evident enthesopathy of the navicular suspensory ligament or radio lucent 
erosions of the navicular bone flexor cortex do not benefit from ESWT. 
TENDONS AND LIGAMENTS - RESEARCH 
Chronic Achilles tendinopathy 
Studies involving ESWT effects on the tendons and ligaments of animals have 
increased in recent years. Orhan, et al used rat Achilles tendons to assess the effects of 
ESWT on tendon healing by observing histological and biomechanical parameters (59). The 
right Achilles tendon of 28 rats were cut and then sutured. Five hundred pulses (14 kV) were 
applied to the Achilles tendon of 14 rats. Fourteen other rats underwent a sham operation 
and served as the control group. The rats were sacrificed 3 or 9 days after ESWT and 
biochemical studies were performed to measure hydroxyproline levels. Hydroxyproline is a 
major component of collagen and provides stability to the triple-helical structure of the 
protein. Levels were found to be higher in the treated groups. The histopathology findings 
and the increased hydroxyproline levels revealed that ESWT might facilitate tendon healing 
after trauma. 
A second study by Orhan induced lesions in the 48 rat Achilles tendons with an 18-
gauge needle and the animals were divided into 3 groups (60). The first group received only 
radiation after the operation and the second group served as untreated controls. The third 
received 500 pulses (15 kV) ofESWT on the second post-operative day. All the rats were 
killed 21 days after surgery. Histopathology results showed an increase in the number of 
capillaries and less formation of adhesions in the ESWT group compared with the control 
group (p = 0.03). Additionally, a significantly greater force was required to rupture the 
tendon in the ESWT group (p = 0.028). 
The effect of shock waves on canine Achilles tendon/bone interface has been studied. 
Wang, et al treated the Achilles tendon-bone junctions in 8 dogs with 1,000 pulses at 0.18 
mJ/mm2 ( 61 ). Biopsies were taken from the treated tendons at 4 weeks and 8 weeks after 
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shock wave application. Microscopic neovascularization and myofibroblasts were found in 
the ESWT-treated specimens 4 weeks and 8 weeks after shock wave application, but none 
were seen in the control specimens. The study concluded that ESWT increases 
neovascularization at bone/tendon interfaces. 
The potential adverse effects of ESWT on tendons and ligaments have been evaluated 
in lab animals. In rabbit Achilles tendon models, dose dependent inflammation resulted with 
EFD greater than 0.28 mJ/mm2 (62). However, EFDs greater than 0.28 mJ/mm2 are used 
routinely in other mammals without complications. In another study using turkey 
mineralized gastrocnemius models, an EFD of 0.6 mJ/mm2 had no effect on the material 
characteristics of the tendon. An EFD of 1.2 mJ/mm2, however, resulted in decreased tensile 
strength (63) . 
TENDONS AND LIGAMENTS - HUMAN CLINICAL APPLICATIONS 
Calcifying tendonitis 
Shock wave therapy has gained increasing acceptance in treating tendonitis and 
desmitis in people. The Food and Drug Administration has approved its use for the treatment 
of plantar fasciitis (64). People with calcification of the rotator cuff are routinely treated with 
ESWT and have experienced dissolution of calcification and subsequent pain relief. Small 
areas of mineralization seen ultrasonographically respond better to ESWT than large areas 
seen radiographically (64, 65, 66). 
Plantar fasciitis (calcaneal, heel spurs) 
Plantar fasciitis is the most common musculoskeletal disorder investigated in recent 
ESWT data. The ability of ESWT to alleviate pain associated with plantar fasciitis is the 
primary focus of most of these studies. One prospective study administered 3 to 5 low 
energy ESWT treatments (0.09-0.18 ml/mm2) to the injured plantar fascia of 85 patients (25). 
A significant decrease in pain occurred after 5 months. 
There has been discussion of how clinical results of ESWT for treatment of plantar 
fasciitis are affected if the patient receives local or general anesthesia (67). Sixty patients 
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with chronic plantar fasciitis were randomly assigned to receive either ESWT without local 
anesthesia (3 x 1500 pulses, EFD 0.09 mJ/mm2 [Group A]), ESWT with local anesthesia (3 x 
1500 pulses, EFD 0.18 mJ/mm2 [Group B]) or ESWT with local anesthesia (3 x 1500 pulses, 
EFD 0.09 mJ/mm2 [Group C]) (68). Group A without local anesthesia showed a significantly 
higher improvement in the VAS and subjective evaluation than groups B and C. A reduction 
of pain of at least 50% was achieved in 60% of group A, in 36% of group B and in 30% of 
group C. At 6 weeks, success rates after low-energy ESWT with local anesthesia (group A) 
were significantly lower than after identical low-energy ESWT without local anesthesia 
(group C). It has been concluded that ESWT should be performed without local anesthesia in 
patients suffering from chronic heel pain as local anesthesia applied prior treatment may 
reduce the efficiency ofESWT. To date, no studies have shown the mechanism responsible 
for the adverse influences that local anesthesia has on ESWT. 
A 2004 study used ultrasound guided ESWT for chronic plantar fasciitis in 51 
patients (69). Numerous subjective measures were used to evaluate pain. Fifty-six percent 
of the treatment group experienced a decrease in pain at 3 months and 94% experienced 
success at 12 months post treatment. The control group reported 47% success at 3 months 
post treatment. A 2005 study evaluated 30 patients with plantar fasciitis refractory to 
conservative treatment modalities after at least 6 months (70). Each patient received 3800 
shock waves into the treated heel with ultrasound guidance. A statistically significant 
improvement was made in the mean VAS up to 124 days after ESWT. Twenty-five of 30 
patients reported some degree of improvement, with 5 experiencing no change. A 2005 
study by Hammer, et al also used ultrasound-guided ESWT on refractory plantar fasciitis 
(71). Twenty-two patients with unilateral plantar fasciitis were treated with 3 weekly 
treatments of 3000 shock waves at 0.2 mJ/mm2• The contralateral plantar fascia was used as 
the control. The treated plantar fascia significantly decreased (p<0.05) in thickness as 
viewed by ultrasound up to 24 weeks later. Pain, based on the VAS, decreased by 79% and 
the comfortable walking time increased, both significantly (p<0.01). A second study by 
Hammer, et al evaluated the effect ofESWT in 44 patients with plantar fasciitis in which 
conservative treatment had failed (72). The patients received 3000 shock waves of 0.12 
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mJ/mm2 3 times at weekly intervals. After a follow-up of 6 months, pain measured on a 
visual VAS decreased significantly and 70% of the painful heels improved. 
A 2002 study out of Germany utilized 32 patients with plantar fasciitis randomly 
assigned into treatment and placebo ESWT groups (73). Treatment included 1000 impulses 
at 0.08 mJ/mm2 at repeated after 6 weeks or placebo (energy-absorbing foil). Eighty-eight 
percent of the treatment group were pain free or had good results up to 48 weeks later. The 
treatment group showed significantly improved morning and resting pain (VAS), pressure 
stamp-tolerance (pedograph), and walking ability. Although 33.3% of the control group had 
good results, none of the subjects were pain free. 
Subcalcaneal spurs occurring secondary to plantar fasciitis have also been treated by 
ESWT in recent studies. A controlled study examined 60 patients with heel spurs (74). 
Thirty patients underwent an ESWT treatment and 30 received a sham treatment. The VAS 
was used to analyze the patients. Results found a significant decrease of VAS in the treated 
group, indicating decrease in pain. Radiographic evidence of reduction of enthesophytosis 
occurred in 9 (30%) group 1 patients. Ultrasonography did not show significant changes in 
the grade of enthesitis immediately after the end of treatment. However, a significant 
reduction was seen after 1 month in the ESWT group. In the control group no significant 
changes were observed on the VAS, radiographs, or ultrasound. ESWT was found to provide 
analgesia, structurally modify enthesophytosis, and reduce inflammatory edema associated 
with heel spurs. 
In numerous studies, ESWT has alleviated pain associated with heel spurs in humans 
while few radiographic changes have been evident (75, 76, 77). A possible explanation is 
ESWT-induced increased osteoblastic activity and subsequent strengthening of subchondral 
bone and thickening of cortical bone (3, 78). 
lnsertional desmopathy - tennis elbow 
The efficacy and safety ofESWT on human "tennis elbow" has been investigated 
extensively in recent years. Tennis elbow is also referred to as insertional tendonitis, chronic 
lateral epicondylitis, and epicondylitis humeri radialis. Furia et al treated 36 patients with 
chronic lateral epicondylitis with a single application of 3200 shock waves (79). Twelve 
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weeks after treatment, pain decreased and functionability increased in 28 of the 36 (77.8%) 
subjects. 
A 2002 study by Decker et al treated 85 patients with a chronic lateral epicondylitis 
with ESWT, which was resistant to previous therapies for at least 6 months (80). Three 
weekly sessions ofESWT were performed under local anesthesia (EFD 0.0~-0.18 mJ/mm2). 
Seventy-eight of the 85 patients could be evaluated subjectively after a mean follow-up of 
30.7 months. Of these patients, 30.8% had an excellent and 42.3% a good result, while 
11.5% had a fair and 15 .4% a distinctly poor outcome. Pain perception assessed by the VAS 
decreased significantly after ESWT (p < 0.0001). Sixty-two of the 85 patients were satisfied 
with their ESWT and would agree to further treatment sessions. 
Hammer, et al evaluated the effect ofESWT on 19 patients with refractory tennis 
elbow (72). Three-thousand shock waves of0.12 mJ/mm2 were delivered to the injured 
elbows 3 times at weekly intervals. After a follow-up of 5 months, pain measured on a VAS 
decreased significantly and 63% of the elbows improved. 
Jnsertional Achilles tendinopathy 
A 2005 study aimed to determine the efficacy of ESWT for the treatment of 68 adults 
with chronic insertional Achilles tendinopathy (81). A total of35 patients were treated with 
a single dose of ES WT (3000 pulses of 0.20 mJ/mm2) while 33 patients were treated with a 
sham procedure. Subjectively, 51 % of the ESWT patients and 39% of the control patients 
were assigned an excellent or good result. This study determined that ESWT is a safe and 
effective treatment for chronic insertional Achilles tendinopathy in humans. 
Supraspinatus tendonitis 
The efficacy of low-energy ESWT on supraspinatus tendonitis without calcification 
has been evaluated in human research. Schmitt, et al performed a controlled, randomized 
study dividing 40 patients into 2 groups of 20 subjects (82). The treated group received local 
anesthesia and 6000 impulses (EFD 0.11 mJ/mm2) divided into 3 sessions. The control 
group had 6000 pulses of sham treatment after local anesthesia. At 6 and 12 weeks, no 
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statistically significant difference was found between the groups with an increase in function 
and a reduction of pain in both groups (p <or= 0.001). 
A similar study by Haake, et al analyzed the effect of ESWT focused on either the 
calcified region or the insertion of the supraspinatus tendon (83). One group consisted of 50 
patients who received 2 sessions of 4000 impulses (EFD 0.78 ml/mm2) to the insertion of the 
supraspinatus under local anesthesia. The other patients received ESWT focused on the 
calcified region. At 12 weeks after treatment, functional improvement and pain reduction 
were found in both groups. ESWT focused on the calcified region showed significantly more 
alleviation of pain and improved mobility. The study concluded that fluoroscopic-guided 
ESWT focused on the calcification rather than on the insertion of the supraspinatus tendon is 
significantly more effective. 
Rotator cuff calcifying tendonitis 
Calcific tendonitis of the shoulder is often associated with chronic pain and 
impairment of function. ESWT is considered to be a viable treatment option. A 2005 study 
by Moretti et al treated 54 patients with rotator cuff calcifying tendonitis with 4 sessions of 
medium-energy ESWT (0.11 mJ/mm2) (84). Pain was evaluated at the end of each session 
while shoulder function was assessed at 1 and 6 months after the end of procedure. Thirty-
eight patients (70%) reported satisfactory functional results. Radio graphs and sonographs 
showed a disappearance of calcium deposit in 29 patients (54%) and a greater than half 
reduction in 19 patients (3 5% ). A correlation was found between residual calcium deposit 
and the clinical outcome up to 6 months follow-up. Some patients, however, showed a 
reduced pain without modification of calcium deposit. This study concludes that medium-
energy ESWT may provide desirable pain modulation in rotator cuff calcific tendonitis. 
A 2004 study compared 2 different ESWT regimens in 43 patients (57 shoulders) 
with symptomatic calcific tendonitis of the shoulder of more than 6 months duration (85). 
Thirty-one shoulders comprising the treatment group received 2 treatments of 2000 impulses 
of 0.28 mJ/mm2 at a 2 week interval. The control group consisting of 26 shoulders was given 
pretreatment analgesia and administered 2000 impulses of 0.07 mJ/mm2• Improvement in 
shoulder function was significantly higher in the treatment group at all follow-up visits (p < 
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0.05) from 1 week to 7 months following ESWT. Radiographs taken 7 months post-
treatment showed that calcifications resolved completely in 19% of the treatment group and 
8% of the control group, and greater than a 50% reduction was observed in 19% and 8% 
respectively. At 1 week, a significant reduction in pain (VAS) was noted in the treatment 
group compared with the control group (p < 0.05). However, at the 3-month and 7-month 
visits, no significant difference in pain between the groups could be detected. The study 
concluded that ESWT with an EFD of 0.28 mJ/mm2 leads to a significantly greater 
improvement in shoulder function and a slightly greater dissolution of calcified deposits 
compared with the control group. This application, however, did not result in reduction of 
pam. 
A similar study by Peters, et al investigated clinical and radiological efficacy of 
different energy levels of ESWT in calcific tendonitis of the shoulder (86). All 90 subjects 
had radiographically verified calcific tendonitis of 1 shoulder, restriction of shoulder 
mobility, and pain for at least 6 months. The subjects were divided into 3 groups. Group 1 
received ESWT at an energy level of0.15 mJ/mm2, group 2 received ESWT at 0.44 mJ/mm2, 
and the control group received sham treatment. Treatment was given at 6 weekly intervals 
until symptoms resolved, 5 treatments had been given, or the subject dropped out of the 
program. All subjects in groups 1 and 2 completed the program. Those subjects in group 1 
(0.15 mJ/mm2) had significantly less pain during treatment but more treatments required than 
those in group 2 (0.44 mJ/mm2). At 6 months, 87% of group 1 had residual calcification and 
recurrence of pain. Subjects in group 2 had no residual calcification or recurrence of pain. 
Sham treatment had no effect. The study concluded that ESWT at an energy level of 0.44 
mJ/mm2 is an effective treatment in calcific tendonitis of the shoulder with few significant 
side effects. 
A 2003 single blind study evaluated ESWT on 70 patients showing chronic, 
symptomatic, calcifying tendonitis of the shoulder (87). Thirty-five patients underwent 
regular EWST treatment (group 1) and 35 received simulated treatment (group 2). The 
results found that ES WT-treated individuals experienced a significant decrease of pain and a 
significant increase in shoulder function. Radiographic examination showed partial 
resorption of the calcium deposits in 40% of cases and complete resorption in 31 % of cases 
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in the ESWT group. The control group showed no significant improvement in pain, function, 
or radiographic resolution of calcium deposits. The researchers considered ESWT as an 
acceptable adjunctive treatment for chronic calcific tendonitis of the shoulder due to its 
clinical radiological response, safety, and tolerability. 
Jakobeit, et al used ultrasound-guided ESWT in 80 patients with chronic rotator cuff 
calcifying tendinopathy (88). The patients were treated 1 to 5 times at an interval of 4-6 
weeks with 1800 shock waves (EFD of 0.08-0.42 mJ/mm2). At the end of treatment, 85% of 
the patients had decreased or absent symptoms. Shoulder calcification completely resorbed in 
57 (71.2%) patients and partially resorbed in 16 patients (20%). The researchers concluded 
that ESWT is a very effective and non-invasive surgery alternative for symptomatic 
calcareous tendinopathy of the shoulder. 
A prospective study with short-term follow-up performed by Pigozzi, et al involved 
72 patients affected by chronic shoulder pain lasting more than 6 months (89). All patients 
received weekly ESWT for 8 weeks with 2,000 impulses (EFD 0.21 mJ/mm2). Based on 
radiographs and the VAS, 53% of the patients scored excellent results, 14% good, 13% fair 
and 20% poor. Thirty-seven percent of the patients with calcifying tendonitis experienced a 
reduction in calcification and 63% had no change. The researchers conclude that even with a 
limited number of cases, ESWT showed to be risk-free and efficacious treatment of chronic 
painful shoulder when resistant to other conservative methods. 
TENDONS AND LIGAMENTS- VETERINARY CLINICAL APPLICATIONS 
Suspensory ligament desmitis 
Proximal suspensory ligament desmitis in horses was one the first equine 
musculoskeletal injuries treated by ESWT and many researchers have found beneficial 
results. In 2004, McClure, et al performed a controlled study to evaluate the healing effects 
ofESWT on collagenase-induced suspensory desmitis (90). Four thousand international 
units (IUs) of collagenase were injected into normal suspensory ligaments in both forelimbs 
of 4 horses and ESWT was administered to 1 forelimb in each horse 3 weeks later while the 
horse's other forelimb served as a control. Three treatments of 0.13 mJ/mm2 at 3 week 
22 
intervals were administered. A 35 mm probe delivered 500 pulses to the palmar aspect and a 
5 mm probe delivered 500 pulses to both the palmar-lateral and palrhar-medial aspect of the 
ligament. Ultrasound revealed a significantly faster decrease in cross-sectional area of the 
ligament lesions in the ESWT-treated limbs up to 12 weeks after ESWT. The subjects were 
then euthanized and the suspensory ligaments were fixed and evaluated histologically. The 
total percent lesion (p = 0.01), total fiber alignment score (p = 0.0167) and total echogenicity 
(p = 0.0023) were all improved in the ESWT-treated ligaments. Additionally, the ESWT-
treated ligaments had a more concentrated area of metachromasia associated with healing 
while the untreated ligaments had a more diffuse area of metachromasia throughout the 
ligament. This study showed that ESWT improves the rate of healing of SULs as assessed 
by ultrasound. 
A Brazilian veterinary research team performed a similar ESWT study on equine 
desmitis in 2005 (91). Two collagenase injections were administered 2 weeks apart into the 
hind suspensory ligaments of 10 horses. The right hind limb of each horse was treated with 
ESWT (3 treatments at 3-week intervals) while the left hind limb served as the control. 
Periodically during the study, the ligaments were evaluated ultrasonographically to assess for 
lesions. Four weeks after the last ESWT treatment, biopsy specimens were collected from all 
ligaments for histology evaluation and immunocytochemical analysis of osteogenic TGF-p. 
Compared with control ligaments, ESWT-treated ligaments had smaller, more newly formed 
collagen fibrils and significantly greater expression of TGF-P (p<0.05) 4 weeks after the last 
ESWT treatment was administered. This study also suggests that ESWT may assist in 
healing in horses with naturally occurring suspensory ligament desmitis. 
The application of RPWT on chronic or recurrent proximal suspensory desmitis was 
evaluated in 65 horses (92). The horses were treated 3 times at 2-week intervals (2000 pulses 
at 10 Hz) and followed a controlled exercise program. Each subject was reassessed clinically 
and ultrasonographically 10 to12 weeks after treatment. Forty-one percent of horses with 
hindlimb lameness and 53% with forelimb lameness improved clinically and returned to full 
work in 6 months. The researchers concluded that although more research is warranted, 
RPWT is a useful treatment modality for chronic or recurrent proximal suspensory desmitis 
when combined with controlled exercise. 
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Superficial digital fiexor tendonitis 
Superficial digital flexor tendon (SDFT) lesions are common injuries in performance 
horses and numerous modalities have been attempted to assist their healing. The efficacy of 
ESWT in treating SDFT tendonitis in racehorses has recently been investigated (93). An 
electrohydraulic generator delivered 150 shock waves per centimeter oflength of the core 
lesions (0.13 to 0.15 mJ/mm2) in the SDFT of 8 horses for 3 sessions at 3-week intervals. All 
lesions showed improvement ultrasonographically. ESWT appeared to speed the rate of 
healing of the significant type 3 core lesion and decreased the cross sectional area of the 
lesion faster than conservative methods. Four of the 8 ESWT treated horses went on to race 
successfully. One horse took a year ofrest before returning to training. Two subjects re-
injured their SDFT and 1 horse retired before returning to training. Horses with acute diffuse 
type 1 tendonitis (slightly more hypoechoic than normal) have also responded very well to 
ESWT (94). Within days of treatment, ultrasonographic evaluation of these tendons revealed 
a prominent decrease of fluid in the tendon. Detectable pain parameters such as heat and 
pain on deep palpation also decreased. 
A blinded controlled study investigated the efficacy ofESWT on collagenous-
induced lesions in the SDFT of 6 horses (95). One thousand IU of collagenase were injected 
into the center of both front SDFT. The maximum injury zone was located and the first 
ESWT was begun 31 days after induction of the lesion. The second and third ESWT 
sessions occurred on days 49 and 70. Each treatment consisted of 1500 pulses at 0.14 
mJ/mm2 focused on the lesion on a randomly assigned forelimb while the other SDFT served 
as a control. The ESWT-treated lesions showed a significant increase in neovascularization 
histologically. Further evaluations of mechanical and histological effects of ES WT on SDFT 
injuries are indicated. 
While the previously described studies involve ESWT and acute tendonitis, some 
equine clinicians promote ESWT for chronic tendonitis or tendon calcification. Studies 
recommend that ligamentous lesions and chronic tendon lesions 4 weeks old or greater be 
treated with EFDs of0.15 mJ/mm2 while acute lesions should be treated with EFDs of0.01 
mJ/mm2 (54). 
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Calcification in the equine ligamentum nuchae 
Training and competing dressage horses are asked to maintain their head flexed at the 
poll. Injuries such as chronic insertional desmopathy and entheseophyte formation at the 
attachment of the ligamentum nuchae on the occipital bone are common in European 
Warmbloods used for dressage (54, 96). Avulsion fractures of the occipital bone and 
subsequent calcification within the supraspinous bursa are often evident radiographically or 
scintigraphically. ESWT has been investigated as a therapy for these disorders of the 
ligamentum nuchae. Brems and Weiss treated 12 equine patients with clinical signs of neck 
pain and radiographic evidence of calcification of the occipital bone or the ligamentum 
nuchae (96). All subjects were treated 3 times at 4 to 8 day intervals with 2000 pulses 
applied to the insertion of the nuchal ligament with the focused shock wave generator. 
Clinical signs completely resolved in 10 of the 12 horses after 20 weeks and they returned to 
normal riding. One horse showed 50% improvement and 1 seemed unimproved. The study 
concluded that insertion-desmopathy of the nuchal ligament can be treated successfully by 
ESWT. Since many horses show radiographic changes of the neck, the success ofESWT 
should be measured by clinical and functional improvement rather than by radiographs alone. 
A separate trial found that horses with ligamentum nuchae abnormalities respond well to 2 or 
3 treatments in 14-day intervals (54). Four weeks post ESWT; the 22 subjects were ridden without 
forced neck flexion and were given non-steroidal anti-inflammatory medication for 8 days following 
each treatment. Four weeks following the final shock wave treatment, signs of neck pain resolved in 
12 of the 22 horses, improved in 6 horses, and showed no change in 4 subjects. Those horses that 
responded well to therapy returned for a fourth treatment 6 to 12 months later and, again, responded 
favorably to ESWT. 
JOINTS - RESEARCH 
Osteoarthritis 
The osteoprogenic qualities ofESWT have been evaluated via in vivo research on 
degenerative bone and joint diseases (3). Recent studies have investigated the efficacy of 
ESWT on equine osteoarthritis ( 4, 92). A study by Mcllwraith compared ESWT to 
polysulfated glycosaminoglycan in treating equine osteoarthritis (97). The positive controls 
25 
were given 500 mg IM polysulfated glycosaminoglycans (Adequan) every 4 days for 28 
days. The shock wave group was administered 2000 shocks at E4 (0.13 mJ/mm2) and 1500 
shocks at E6 on days 14 and 28, respectively. The negative control group received no 
treatment. Osteochondral fragments were experimentally induced on the distal radial carpal 
bone in each subject. Clinical lameness assessment 14 days post treatment showed 
significant improvement in the ESWT group versus positive or negative controls. Both the 
positive control and the ESWT group continued to improve in lameness evaluations up to 42 
days after the last treatment. By 70 days from the start of the study, the ESWT horses had 
significantly lower synovial fluid protein than the negative and positive control horses. These 
results indicate reduced synovitis and capsulitis with ESWT. This study suggests that ESWT 
has more of an effect on periarticular soft tissues rather than articular cartilage and is 
effective for reducing clinical lameness and synovitis but not histologic arthritis progression. 
It is, therefore, suggested that ESWT be used in conjunction with a chondroprotective agent 
for osteoarthritis (97). 
JOINTS - HUMAN CLINICAL APPLICATIONS 
Heterotrophic ossification 
ESWT has been utilized in numerous periarticular and intra-articular diseases and for 
the alleviation of pain associated with these diseases (50, 98, 99). Heterotrophic ossification 
(HO) is the formation of bone within extraskeletal soft tissues. The exact mechanism for 
these changes is unknown. Localized HO occurring secondary to damage to the nervous 
system, such as spinal cord injury, is called neurogenic. Non-neurogenic HO occurs from 
direct injury to the muscles. Fibrous, cartilaginous, and osseous tissues near bone are 
affected (100). A 2005 study by Brissot, et al evaluated ESWT on 26 patients with HO of 
the hip joint (101 ). The subjects received once weekly sessions of ESWT ( 4000 pulses, EFD 
0.54 - 1.06 mJ/mm2) for 4 consecutive weeks. Heterotophic ossification was neurogenic in 5 
patients and non-neurogenic in 21. Pain ( on the VAS), joint flexion, and walking distance 
significantly improved in the subjects. Radiographs did not show significant changes 
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between treatments. This study showed that ESWT could complement medical treatment, 
physiotherapy, and pre-surgery therapy for hypertrophic ossification. 
Osteoarthritis 
Objective in vivo studies examining the effects ofESWT on clinical osteoarthritis in 
humans are lacking in published literature. 
JOINTS- VETERINARY CLINICAL APPLICATIONS 
Osteoarthritis of tarsometatarsal ioint (bone spavin) 
Early use of ESWT on horses involved treatment of hock lameness. McCarroll and 
McClure placed 74 horses with lameness grades of 1 to 3 (0 to 5 scale) under general 
anesthesia and administered 2000 pulses at 0.89 mJ/mm2 in each of the 4 joints in their hocks 
(17). The probe was directed toward the radiographically evident hock lesions. At 90 days 
post ESWT, 80% (59 of the 74) horses improved 1 lameness grade or more. Horses with 
osteophytes on the dorsal to dorsomedial aspect of the tarsometatarsal joint improved the 
most. Of the 15 non-responsive horses, 8 horses received an additional shock wave treatment 
and 4 of these horses improved. This study proved that ESWT alone (80% lameness 
resolution subjective evaluation) is equally as effective in resolving lameness as surgically 
facilitated ankylosis (79% lameness resolution) and chemically facilitated ankylosis (80% 
lameness resolution). The advantage ofESWT is the non-invasive nature of the treatment 
(102, 103). Some researchers hypothesize that ESWT may result in remodeling and assisted 
ankylosis. ES WT-enhanced osteoblastic activity results in thickening of cortical bone (3). 
Additionally, the subchondral bone remodels and strengthens in response to loading, absorbs 
shock, maintains joint shape, and protects cartilage from damage (56). These researchers 
conclude that these bony changes may be responsible for resolving lameness. Despite 
improved joint function, radiographic changes are not always evident. This decrease in 
lameness in the absence of radiographically evident changes has also been noticed with 
ESWT-treated heel spurs in humans (75). 
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Simultaneous intra-articular therapy and ESWT has been performed with an additive 
effect, whether injected before or after ESWT (54). With the horse standing, the affected 
hock was palpated and 800 to 1000 pulses at 0.15 mJ/mm2 were administered to the entire 
tarsometatarsal region. Intra-articular medication may be injected before or after ESWT 
during the same visit. Researchers suggest that ESWT may be used on equine hock arthritis 
unresponsive to medical therapy alone. 
Canine osteoarthritis 
ESWT has also been used to treat dogs with osteoarthritis of the hip or elbow joint 
(104). Nine dogs with hip and elbow arthritis were either treated 3 times with ESWT at 2 
week intervals or served as controls. The treated dogs showed a 20% improvement over 
baseline force platform measurements while the control dogs showed decreasing force 
platform values indicating increasing lameness. 
The canine stifle is frequently affected with osteoarthritis. A group of dogs with 
consistent osteoarthritis offers a more controlled study population to investigate the effects of 
ESWT on osteoarthritis. However, additional studies are required to define this role. The 
objective of the publication presented in Chapter 3 of this thesis is to evaluate ESWT on 
osteoarthritis of the canine stifle in a blinded controlled study. An objective examination of 
the results is performed by force platform analysis. 
OTHER ESWT APPLICATIONS 
Skin 
Low EFD shock waves have resulted in re-epithelialization of partial thickness 
wounds (105). Meirer et al investigated the effect of ESWT on compromised epigastric skin 
flaps of 20 rats (106). The rats were divided into 2 groups (ESWT group and control group). 
The ESWT group received 2500 impulses (EFD 0.15 mJ/mm2) immediately after surgical 
elevation of the epigastric skin flap. The control group received no treatment after surgery. 
Seven days after ESWT, the treated skin flaps had significantly reduced surface areas of 
necrosis compared to the control groups (p < 0.01 ). This study suggests that ESWT is a 
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feasible modality to improve blood supply in ischemic tissue. A case study performed by the 
same research group evaluated the efficacy of treating partial thickness bums with ESWT. 
One thousand-five hundred pulses (EFD 0.11 mJ/mm2) were applied to the right forearm of a 
31-year-old man who had suffered partial thickness bums while using hot cooking oil. The 
bum area was treated at days 3 and 7 after the injury. The majority of the surface area of the 
bum had re-epithelialized by day 15 after the injury. At 6 months, the bum area had healed 
without scarring (107). 
Haupt et al also displayed the re-epithelialization capabilities of low energy shock 
waves on animal skin models (105). Split thickness wounds were made with an 
electrokeratome in 3 Yorkshire piglets and a fourth piglet was used as a model for delayed 
healing by irradiating the skin before the wounds were created. Ten to 1000 shock waves 
were delivered at 14- or 18-kV to each wound on each piglet. The animals were euthanized 
and the skin wounds were evaluated histologically. The wounds treated with low-dose 
ESWT (10 pulses at 14kV) showed significant enhancement in both the normal and 
irradiated specimens. High dose applications (100 pulses at 18kV) inhibited healing of both 
groups. Histologically, the low dose ESWT resulted in increased vascularization of the 
dermis and increased thickness of the epidermis over the wounds. 
Back pain 
Focused ESWT has been used to treat origins of back pain in horses. The probe may 
be focused on visible areas of bone sclerosis or insertional desmitis identified by radiographs, 
ultrasonography, and scintigraphy. It may also be used to locate painful muscular lesions 
that are not identifiable by these diagnostic tools (108). Clinical response to treatment 
depends on the severity of the lesions and conformation of the horse and the number of 
pulses and the probe size should be appropriate for the size and site of the back lesion. In the 
noted study, 50 pulses were directed to both sides of a 1 cm long area of bone sclerosis on a 
dorsal spinous process (54). Up to 5 treatments at 2 to 4 week intervals for up to 3 months 
have been used. It is suggested that well muscled horses with mild pain as detected by the 
rider benefit from 1 to 2 treatments at 0.15 mJ/mm2• Severely affected horses require 
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additional treatments, should receive modified training programs, and have a 65% chance of 
returning to normal work. 
Soft tissue back pain may also be addressed by ESWT in performance horses. Probes 
. 2 between 20 mm to 80 mm with EFDs up to 0.15 ml/mm and 2000 pulses have been 
administered (54). The probe is moved over the affected area until the horse responds with 
muscle fasciculations. The probe is held in that location for 80 pulses before moving. With 
this method of probe placement, horses with muscle fasciculations showed nearly 100% 
improvements for up to 10 months as reported by the rider 
ESWT EFFECTS ON ANALGESIA 
The analgesic effects of ESWT were discovered inadvertently during its application 
for orthopedic disease (109). The pain-relieving properties ofESWT are believed to be the 
dominant therapeutic quality of ESWT in the treatment of humeral epicondylitis, plantar 
fasciitis, and heel spurs in people (109). During its extensive use, the presence of anti-
nociceptive effects after ESWT has been described. However, the exact mechanisms and 
duration of analgesia have yet to be defined. Clinically evident analgesia after ESWT varies 
among subjects as well as among treatment locations. The short-term analgesia following 
ESWT may occur for reasons unrelated to the mechanisms that result in healing. 
Analgesia - potential mechanisms 
Neural/Perineural inflammation 
Perineural inflammation or nerve disruption could result in analgesia. Schelling et al 
applied shock waves directly to sciatic nerves of frogs in vitro (l l 0). The study concluded 
that action potentials generated from the nerves were due to gas bubbles elicited by the shock 
waves and not from the action of the shock waves themselves. 
Bolt et al suggested that axonal swelling might cause the analgesia and alter 
peripheral pain perception in horses after ESWT (111). The group treated the forelimb 
palmar digital nerves of 6 horses with RPWT. Three and 7 days after ESWT, the conduction 
velocity along the palmar digital nerves was significantly slower. Transmission electron 
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microscopy of treated nerves revealed significantly more axonal swelling up to 35 days after 
treatment. 
In a sheep study model, McClure et al also found significant perineural inflammation 
and axonal swelling up to 4 days after treating the mid-cannon bone area of 30 sheep with 
ESWT and RPWT. This group found that RPWT produced significantly more nerve 
inflammation than ESWT or controls (112). 
Cutaneous/Local effects 
Conflicting results have occurred with studies investigating the local effects of ESWT 
or RPWT-induced analgesia. The results of these studies suggest that the analgesic effects of 
pressure waves may depend upon the characteristics of pressure wave used. 
Bolt treated the third metacarpal bone of 12 horses with 2000 pulses of RPWT and 
tested limb withdrawal reflex latency using thermal stimulation (113). The other metacarpus 
served as a control. No significant difference existed between treated and untreated limbs. 
Brown et al also used RPWT when treating 9 horses with unilateral navicular syndrome 
(114). One thousand five hundred pulses at 10 Hz were applied through both the frog and 
heel bulbs and force platform analysis was used to objectively analyze changes in lameness 
for 7 days. The study found that 1 treatment of RPWT had no influence on short term 
analgesic in horses with navicular syndrome. 
Conversely, McClure detected local analgesic effects after ESWT (112). The study 
administered ESWT (1000 pulses at 0.15 mj/mm2), RPWT (0.16 mj/mm2), or sham treatment 
to the metacarpi of 6 horses and studied electrical stimulus response. While the RPWT and 
sham group had no effect on local analgesia, ESWT resulted in trends towards local 
cutaneous anesthesia between days O and 3 after a single treatment. Waldem also utilized 
both ESWT and RPWT and evaluated skin sensitivity to electrical stimulation distal to the 
treatment site (115). No analgesia following ESWT or RPWT of the palmar digital nerve 
was detected. The variability of results among these studies suggests that local cutaneous 
analgesic effects may depend upon the different techniques used to generate the pressure 
waves. 
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Depletion of neuropeptides 
Inconsistent findings have been made when evaluating the role of neuropeptides in 
pressure wave-induced analgesia. Substance P (sP) and calcitonin gene-related peptide 
(CGRP) neurotransmitters are found in small diameter afferent nerve fibers. These afferent 
fibers contribute to pain sensation by conducting impulses through the nerve (116). SP and 
CGRP have been isolated in the periosteum, marrow and cortex of long bones (117). 
Substance P innervation has been located in areas of osteoarthritis in horses suggesting its 
role in signaling and maintaining pain (118). 
In 2001, Ohtori et al investigated the ability ofESWT to produce analgesia due to 
morphologic changes it produces in cutaneous nerve fibers (119). Nerve fibers 
immunoreactive for protein gene product (PGP) 9.5 as well as CGRP innervate normal rat 
skin. After ESWT, there was a loss of PGP 9.5 and CGRP in the skin indicating nearly 
complete degeneration of intracutaneous nerve fibers. This study suggests that analgesia 
associated with ESWT may involve depletion of neuropeptides. 
Neuropeptide studies performed in sheep models have also had contrasting results. 
One thousand pulses ofESWT at 0.15 mJ/mm2 or 1000 pulses ofRPWT at 0.16 mJ/mm2 
were delivered to the mid metacarpal/metatarsal regions in 30 sheep (112). The skin, 
periosteum, and nerves were harvested from 2 sheep immediately after treatment and at daily 
intervals for 14 days in the remaining 28 sheep. The concentration of substance P was 
measured. There was no difference in substance P and CGRP concentration between treated 
and non-treated limbs questioning the role of neurotransmitters and nerve fiber depletion in 
post-ESWT or RPWT analgesia. 
Gate control theory 
A "Gate Control Theory" has also been postulated and suggests that analgesia results 
when pain stimuli from small afferent nerve fibers are modulated or disrupted by large 
afferent nerve fibers and descending spinal pathways as they enter the substantia gelatinosa 
(121). Consequently, transmission of the pain stimuli to ascending spinal pathways in the 
dorsal horn is blocked or gated (66, 120). 
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Haake et al investigated the possible influence of low-energy ESWT on inhibition of 
the expression of the sP and CGRP in presynaptic neurons in the lumbar spinal cord of the rat 
(121). The animals were treated either once with 1000 pulses (0.043 mJ/mm2) or 3 times 
with 1000 pulses (0.11 mJ/mm2). The animals were then sacrificed at either 4 or 72 hours 
after treatment. Immunohistochemical analysis of the expression of the sP and CGRP and 
revealed no regulatory effects ofESWT on either neuropeptide in the dorsal horns of the 
treated rats. The study concluded that due to the absence of significant changes in the 
sensory system, it is unlikely that the application of ESWT triggers the endogenous pain 
control system of the rat through hyperstimulation analgesia. 
Another analgesia study by Haake et al investigated whether the long-lasting 
analgesic effects of ESWT involved the gate control mechanism. Transcription factor c-Fos, 
which interferes with the molecular expression pattern of neurons, was utilized as a marker 
for neuronal activity in the study. ESWT at and EFD of 0.33 mJ/m2 was focused on the paws 
of rats and c-Fos expression was analyzed in the dorsal horn of the spinal cord. Regardless 
of EFD, c-Fos protein expression did not vary in the dorsal horn from 4 to 72 hours after 
ESWT. Furthermore, the mRNA of the c-Fos protein did not change expression in the 
treatment area of the paw. The study concluded that ESWT with an EFD up to 0.33 mJ/mm2 
does not modify neuronal activity and ESWT is unlikely to induce stimulation-produced 
analgesia via the gate control mechanism (122). 
Endogenous spinal opioid system 
The aim of the 2001 study by Haake was to investigate if the analgesic effect of 
ESWT is caused by modulation of the endogenous spinal opioid system (123). Rats were 
treated with 2 different EFDs (0.04 and 0.1 lmJ/mm2) and immunohistochemical analysis of 
met-enkephalin (MRGL) and dynorphin (Dyn) was performed at 4 or 72 h after ESWT. 
ESWT did not alter MRGL or Dyn immunoreactivity in the spinal cord at either EFD 
regardless number of pulses or treatment sessions. Furthermore, a delayed effect of ES WT at 
72 hours after treatment was not detectable. The study suggested that the analgesic effects of 
ESWT do not involve the modulation of endogenous opioids 
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Analgesia - presence and duration 
Numerous hypotheses have been proposed as to the mode of analgesic action 
induced by ESWT. None, however, have been truly proven. The presence of anesthesia 
after ESWT in horses has not yet been defined. The importance of this data applies to both 
horse and rider as risks may be involved if pain comprehension by the horse is absent during 
performance. Regulations based on empirical data have been implemented in multiple horse 
racing jurisdictions due to these dangers. Therefore, further objective evaluations of the 
analgesic period following ESWT in horses are needed in the literature. The main objective 
of the manuscript in Chapter 4 is to measure the duration of acute analgesia following a 
single session ofESWT in horses with naturally occurring unilateral forelimb lameness. 
Cutaneous analgesia 
Effects of cutaneous analgesia appear to depend upon the technique used to generate 
the pressure waves. A 2004 study by Bolt et al aimed to determine the onset, magnitude, and 
duration of cutaneous analgesia after RPWT (113). A single RPWT treatment was applied 
over dorsal aspect of 1 metacarpus in 12 horses. The limb withdrawal reflex latency 
(L WRL) assessed cutaneous sensation in the treated and untreated metacarpi by using a 
focused light source. No significant difference in decrease ofLWRL over time was found 
between treated and control areas compared with baseline values. The study suggests that 
cutaneous analgesia does not occur after RPWT application to the equine metacarpus. 
McClure et al also studied equine skin sensation in the treatment region over the 
middle aspect of the third metacarpal bone (112). However, McClure used focused ESWT as 
well as RPWT and electrical stimulation. A constant current was delivered to the skin 
surface at the treatment site between the heel bulbs. The milliampres were increased until the 
horse acknowledged the current. Acquired analgesia was detected if a greater current was 
required to elicit a response in the horse. A baseline measurement was achieved in each 
horse by averaging the measurements taken for 3 days before the beginning of ESWT or 
RPWT. Then the horses were treated with ESWT or RPWT and measured daily for the next 
7 days. A difference from baseline for both ESWT and RWPT was detected for the first 4 
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days following treatment. The study indicates that cutaneous analgesia may be achieved up 
to 4 days following ESWT and RPWT. 
Duration of analgesia 
The characteristics and duration of analgesia after ESWT varies among individuals 
and among musculoskeletal treatment locations. Buch et al found that direct post treatment 
analgesic effects of shock wave therapy on heel spurs may last for up to 3 or 4 days (75). 
Ogden, however, explained a bimodal analgesic response after treating human patients for 
heel spurs (124). Patients reported a decrease in pain for 3 to 4 days after treatment, and then 
a gradual return of pain followed by a decrease in pain as healing occurred. 
Brown et al used a force platform to determine the duration of analgesia after RPWT 
in horses with navicular syndrome. One thousand five hundred pulses of non-focused RPWT 
(10 Hz) were delivered to the frog and heel bulb. Ground reaction force measurements were 
recorded at 15 minutes and at 24-hour intervals for 7 days. The results showed no difference 
in lameness between treated and untreated limbs after a single RPWT treatment (114). 
Lischer et al assessed limb load distribution in equine subjects using an instrumented 
treadmill after ESWT was applied to proximal suspensory desmitis (125). Force plate 
analysis revealed that analgesia lasted 3 days after ESWT. Twenty-four hours after ESWT, 
analgesia was comparable to local or perineural analgesia. 
POTENTIAL COMPLICATIONS OF ESWT 
Potential adverse effects of ESWT on tendons and ligaments of laboratory animals 
have been discussed previously. The effects were seen at EFD greater than 0.28 mJ/mm2, 
which have not shown to be detrimental to larger mammals (62, 63). Tissue necrosis may 
occur at excessive energy levels (126). Haake et al systemically recorded the side effects of 
ESWT in the treatment of tennis elbow in a randomized, placebo-controlled study (127). 
More side effects were documented in the ESWT group than in the placebo group and 
included mild reddening of the skin (21.1%), pain (4.8%) and small hematomas (3.0%). The 
researchers also report the unlikely occurrence of migraine or syncope after ESWT. ESWT 
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commonly used for tennis elbow with an EFD from 0.04 to 0.22 mJ/mm2 has very few side 
effects. 
Shock waves should never be directed at gas/tissue interfaces such as lung and 
intestine (128). Lung bleeding is the most serious side effect when shock waves are used to 
fragment gallstones in dogs. Delius placed pressure probes into dogs between the lung and 
the diaphragm. Shock wave pressures over 2 MPa could be administered safely, whereas a 
pressure of 10 MP a caused bleedings in small to medium sized dogs. The acoustic 
impedance of soft tissue is markedly greater than that of air. Thus, maximum acoustic 
pressure is reflected at the air/soft tissue interface and serious tissue damage may result. 
A 1993 study found that ESWT might damage arterial intimal membranes (129). 
When human umbilical cords were exposed to shock waves of varying EFDs, grossly visible 
hematomas and superficial holes appeared. Histologically, vessel wall necrosis and rupture, 
and complete detachment of endothelial cells were observed. An EFD of 0.3 mJ/mm2 is the 
lower threshold for the occurrence of severe vascular damage. Additional complications of 
ESWT include premature closure of physes in laboratory animals (130). Therefore, active 
physes should be avoided (54). Finally, mild cutaneous petechiation is a common, yet 
benign, side effect encountered in shock wave studies and procedures performed on animals 
and humans (80, 127). 
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Summary 
Extracorporeal shock wave therapy (ESWT) has expanded from the original uses of 
human urinary calculi treatment to veterinary orthopedic applications. This paper 
investigates the feasibility and efficacy of treating dogs with osteoarthritis of the stifle joint 
with ESWT. In this study, dogs with persistent stifle lameness despite previous surgical or 
medical treatment were either treated with ESWT or served as untreated controls. The more 
lame rear limb of each dog was determined by force platform analysis. The range of motion 
of the stifle joints was assessed by goniometry. Force platform gait analysis and goniometry 
were performed on both groups for 4 visits at 3-week intervals and a final examination 4 
weeks later. Shock wave therapy was performed 3 times on the treated dogs, once at each of 
the first 3 examinations. A placebo treatment consisting of clipping and wetting the hair was 
performed on the control dogs. The vertical forces were evaluated for objective analysis of 
treatment response. For peak vertical force (PVF), 4 of 7 treated dogs improved, while only 1 
of 5 of control dogs improved. The PVF for the within group analysis did not show any 
significant change for the treated group; however, the control group has a significant 
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decrease (p=0.05) in PVF consistent with an increase in lameness. The range of motion 
(ROM) of the stifle joint improved in 5 of 7 treated dogs and 3 of 5 controls. Dogs in the 
treated group had a trend toward increased ROM (p=0.07) and a "positive slope" when 
compared to dogs in the control group which did not have a significant change (p=0. 78) and 
had a negative slope indicating the dogs were developing a decrease in ROM. The subjective 
data provided by client questionnaire did not show significant difference between groups. 
Introduction 
Extracorporeal shock wave therapy (ESWT) was developed for fragmentation of 
urinary calculi in the 1970s ( 4). Subsequent investigations have evaluated ESWT for the 
treatment of various musculoskeletal disorders in both humans and animal species (6, 10, 
13). In humans, ESWT has resulted in long-term decreased pain in patients with plantar 
fasciitis, lateral epicondylitis, calcifying tendonitis and clinical improvement in patients with 
femoral head necrosis where effects were still apparent at 1-year follow-up examination (11, 
17, 18, 19, 20, 21). The exact mechanisms by which ESWT affects tissue are not completely 
understood. The bone-tendon interface in dogs has been shown to have an increased 
neovascularization following treatment (23). To date, the primary use in veterinary medicine 
has been in for equine musculoskeletal diseases, such as distal hock osteoarthritis, suspensory 
desmitis, and stress fractures (12, 13, 14). When applied to osteoarthritis of the 
tarsometatarsal joint and distal intertarsal joints in horses, ESWT has been shown to decrease 
lameness in 80% of the horses (12). 
In research studies using dogs as models, it has been found that ESWT can affect 
bone formation (8). In a radius non-union model in beagles, 100% (5 of 5) of the ESWT 
treated dogs reached radiographically observable bony union 12 weeks post treatment 
compared to only 1 of 5 control dogs (8). Clinically, ESWT has proven beneficial in treating 
multiple bone disturbances when surgery is not viable or when implants are not feasible. 
Furthermore, previous studies performed on dogs have suggested ESWT is beneficial in the 
treatment of delayed or non-union fractures. These initial experiences have revealed than 
ESWT assists in hard callus formation of mid-diaphyseal and supracondylar defects less than 
51 
5mm in gap width. Additionally, a case report documented that a non-union can be 
stimulated to heal following ESWT (10). ESWT has also been used to treat dogs with pain 
from osteoarthritis from hip and elbow osteoarthritis, with treated dogs showing a decrease in 
lameness (3, 10). 
Stifle joint lameness in dogs is most commonly the result of instability and 
osteoarthritis, associated with rupture of the cranial cruciate ligament. Multiple surgical 
techniques have been described that attempt to surgically re-establish joint stability following 
CCL trauma (9). The objective of surgery is to improve limb function and preventthe 
development of, or delay further progression of pre-existing osteoarthritis in the joint. 
Despite repair, osteoarthritis generally develops and progresses with some patients having 
persistent lameness. Commonly used management options for these dogs include weight 
reduction, exercise modification and management of pain and inflammation using non-
steroidal anti-inflammatory drugs (NSAIDS), parenteral administration of 
glycosaminoglycan products, or oral supplementation with nutraceuticals (16). Prolonged use 
ofNSAIDs can contribute to gastric ulceration or renal papillary necrosis and the response to 
parenteral administration of glycosaminoglycans is variable (2, 7, 16). If ESWT can 
decrease the lameness associated with chronic stifle disease, dogs affected would be less 
dependent on pharmaceutical therapies. The objective of this study was to evaluate ESWT as 
a therapy for stifle lameness in dogs with osteoarthritis of the stifle. 
Materials and Methods 
Subjects - In the study 14 client-owned dogs that had chronic lameness localized to 
the stifle joints secondary to osteoarthritis. To be included the dogs had to be greater than 
18.18 kilograms ( 40 pounds) in body weight, in good health other than the diagnosed 
lameness attributable to the stifle joint, have a history of lameness for greater than 6 months, 
and have a visible gait abnormality in the affected limb. The dogs were included ifthere was 
stifle osteoarthritis present or if surgery had been performed bilaterally providing that they 
were predominantly lame in 1 limb. They were excluded ifthere had been an injection into 
the joint within 90 days, surgery on the joint in 180 days or if they had been treated with 
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topical or systemic medications such as oral corticosteroids, non-steroidal-anti-inflammatory 
drugs, glucosamines or antibiotics 14 days prior to starting the study. After confirmation of 
eligibility for entry into the study, the dogs were randomly assigned to the treatment or the 
control group. Physical examination and stifle radiographs were completed to ensure that 
osteoarthritis was present. The most severely affected limb of each subject was determined 
by force plate analysis. The Iowa State University Animal Care and Use Committee 
approved this study. 
Fo_rce platform gait examination- Force platform gait analysis was performed using a. 
biomechanical platformi embedded in an 8-m walkway. Three sets of retroflective photocell 
receptors, were attached 1 meter apart in series and positioned in the walkway, with the 
middle sensor positioned at the middle of the force plate, and were used to determine velocity 
and acceleration over the 2-m measurement regionii_ The dogs were walked across the 
platform at a comfortable speed and ground reaction forces for the forelimb and hind limb 
stance phases were recorded for each passiii. Passes were repeated until 5 valid 
measurements were obtained for each limb (trial velocity between 1.20 to 1 .40 mis; 
acceleration variation+/- 0.5 m/s2• A trial was considered valid if a forelimb and ipsilateral 
hind limb foot strike were isolated on the force plate consecutively. The first valid passes 
were used for analysis. The ground reaction forces in the vertical direction were normalized 
for the dogs ' body weight and used for analysis of limb function. Then data evaluated were 
peak vertical force (PVF, NIO0*N/N units/s), vertical impulse (VI, N/s(s)) and average 
falling slope (AFS, Nim * sec). 
Range of motion- Before sedation, goniometry was performed on the stifle of all 
dogs. Each subject was positioned in lateral recumbency with the study limb uppermost. The 
maximum degrees of joint extension and flexion were recorded. Range of motion extremes 
were identified by the first negative behavioral response (e.g. turning of head, pulling leg 
away) of the dog. The difference was determined as the range of motion and was measured at 
each visit. 
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Client questionnaire - The clients were required to complete a pre-treatment and 4 
post-treatment questionnaires at the respective visits. They were also asked to score multiple 
daily activities with regard to pain in the joints, stiffness, activity level and comfort level. A 
score of' l' designated as most severe and absolute hesitation while a score of '7' correlated 
to no hesitation at all. 
Treatment-The dogs were heavily sedated with a combination ofxylazineiv at 0.55 
mg/kg, butorphanol tartratev at 0.44 mg/kg, and glycopyrrolatevi at .01 mg/kg or 
medetomidinevii at .01 mg/kg administered intravenously. Sedation was performed on control 
subjects as necessary for radiography at the initial visit. The dogs in both groups were 
clipped over the stifle joint. Coupling gel was applied and 200 shock waves were applied at 4 
sites caudolaterally, dorsolaterally, dorsomedially and caudomedially using a probe with a 
focal pressure depth of 20 mm. This was followed by another 700 shockwaves divided into 
the same locations, at a focal depth of 5 mm with a frequency of 4 pulses per second, with an 
energy flux density of 0.14 mJ/mm2, for a total of 1500 pulses. Three treatments were 
repeated at 3-week intervals from visit 1 to visit 3. After treatment, the dogs were either 
allowed to recover spontaneously or when appropriate, had their drug effects reversed with 
yohimbineviii at 0.55 mg/kg or atipamazoleix at .011 mg/kg administered intramuscularly. 
Follow-up examination - After an initial pretreatment visit, each dog returned 4 times 
at days 21, 42, 63, and 98 for evaluation for force plate evaluation, goniometry, and further 
ESWT if assigned to the treatment group. The dogs in the treatment group were treated a 
total of 3 times. The owners were not informed as to the group their dog had been assigned 
until the study was complete. 
Data analysis - The age and weight of the treatment and control groups were 
compared using t-tests. The pre-treatment data were compared to the data from the final visit. 
In order to compare differences between groups, the treatment and control groups were 
compared using a matched pair t-test that adjusted for differences in baseline between 
groups. Additionally, a matched pair t-test was used to compare within group changes. To 
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evaluate the trend of the data between the treated and control groups, the slopes of the change 
in the data over time were calculated for each parameter for each dog. The subjective data 
provided from the client questionnaires was evaluated by a one-way analysis of variance. 
Data were considered significant at p SO.OS; a trend was defined asap-value from 0.05 to 
0.1. 
Results 
Fourteen dogs were enrolled in the study and 12 dogs successfully completed the 
study. One dog was removed for health reasons not associated with the study and another 
dog was refractory to repeated examinations. The treated group consisted of 4 spayed 
females and 3 castrated males with a mean age of 7.6 yrs (range 5.5-9 yrs) and a mean weight 
of 40.6 kg (27-65.9 kg). The dogs represented 6 breeds (Rottweiler, Labrador and 
Chesapeake Bay Retrievers, Newfoundland, Dalmatian, Boxer) and 1 mixed breed dog. The 
control group had 4 spayed females and 1 castrated male. They were a mean 9.6 yrs of age 
(7-13) and 44.7 kg (25.6-63 kg). There were 2 Rottweilers, and 1 Golden retriever, 1 
German Shorthair Pointer, and 1 mixed breed dog. There was no significant difference in age 
(p = 0.13) or weight (p = 0.55) between the treatment and control groups. Five of the 7 
treated dogs and 4 of the 5 control dogs had bilateral osteoarthritis. 
While the majority of treatments were carried out without complications, mild 
discomfort was evident in 2 of the treated dogs immediately following treatment. One dog 
showed subtle reluctance to use the treated limb the night after his second ESWT. However, 
after the third treatment, the dog was unaffected. A second dog had some petechiation on the 
medial stifle. These signs resolved within 24 hours. 
PVF increased in 4 of 7 treated dogs, while an increase was measured in only 1 of 5 
of control dogs (Figure 1 ). For PVF, a significant difference was not found between the 
groups; however, the dogs in the control group had a significant decrease (p=0.05) in PVF 
consistent with an increase in lameness in the control dogs (Table 1 ). VI significantly 
increased in both treated and control groups and no difference was found between groups. A 
significant change in AFS was not found within, or between, groups. The ROM of the stifle 
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joint improved in 5 of 7 treated dogs and 3 of 5 controls (Figure 2) with the dogs in the 
treated group having a trend toward increased ROM (p=0.07) and a positive slope (3.34), 
compared to the control dogs which did not have a significant change (p=0.78) and had a 
negative slope (-1.26). This difference was not significantly different between groups (Table 
1). The subjective data provided by client questionnaire did not show significant difference 
between groups (Table 3). 
Discussion 
Although the dogs in the "treatment group" demonstrated some improvement the 
level of improvement did not reach statistical significance. In contrast, the dogs in the sham 
treatment group did not improve and their limb function worsened significantly over the 98 
day study. This is likely attributable to continued inflammation in the affected stifle 
secondary to progressive osteoarthritis. With this in mind, one could argue that ESWT 
treatment did not lead to improvement but it did seem to attenuate the progression of the 
disease. Certainly the limited sample size and variation in lameness severity in both groups 
contributed to our difficulty in achieving statistical significance for many measured variables. 
The graph of the data for PVF (Figure 1) indicates that improvement was evident at 21 days 
and continues to be more evident at each subsequent treatment. Continuation of treatments, 
more pulses or higher energy at each treatment, or a longer follow-up period may have 
resulted in statistically significant differences in the PVF. 
The results of this study were similar to a previously described canine ESWT study 
(3). A group of 9 dogs with hip and elbow osteoarthritis were used in a 28 day study in 
which dogs were given ESWT 3 times at 2 week intervals. The dogs treated with shock 
wave therapy showed improvement from 2 to 20 % over baseline force plate measurements 
compared to control dogs that were typically less (more lame) than baseline measurements. 
Significant differences were achieved from that report between treated and control subjects 
because PVF and ROM improved from day Oto day 28. (3) One obvious difference between 
the studies was the joints studied. It is possible that the mechanism of inflammation and OA 
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is different between the joints and that ESWT will be more effective for OA in the elbow or 
hip as compared to OA in the stifle. 
The reason for improvement is not known. Shock wave therapy does not seem to 
slow progression of osteoarthritis but it does decrease the pain. This has been shown in a dog 
with coxofemoral osteoarthritis that had less lameness following treatments, but the disease · 
progressed radiographically (10). However, the dogs in the study presented here in this study 
were not radio graphed at the completion of the study and it is unlikely that there would be a 
detectable change over the short period of this study. In addition, it has been reported that 
the severity of osteophytosis as noted on radiographic evaluation of the stifle does not have 
any correlation to limb function (5). 
It is common for dogs with cruciate ligament disease to develop bilateral ruptures of 
the cranial cruciate ligament. Based on the history provided by the owner, and the physical 
examination performed during the initial visit, the limb to be treated was selected. It would 
have been ideal to evaluate only dogs with unilateral lameness, because dogs with bilateral 
disease could have shifting leg lameness, making it more difficult to identify improvement 
seen with the therapy. However, we found recruitment of dogs with unilateral lameness from 
osteoarthritis in the stifle to be very difficult. 
Multiple mechanisms have been suggested for the efficacy of ESWT, but there is 
little scientific evidence available. In a carpal osteochondral fragment model in horses, joints 
that had been subjected to shock wave treatment had significantly decreased lameness and 
decreased synovial fluid total protein than had the untreated carpi (15). Assuming similar 
mechanisms are occurring in dogs, the shock wave therapy would appear to help decrease 
inflammation in the joint. Furthermore, because there is only the potential for mild adverse 
reactions, ESWT could be used repetitively in these cases. There are only reports of transient 
discomfort and mild petechial hemorrhage as side effects ofESWT (22). 
Evaluation ofESWT therapy on osteoarthritis of the canine hip and elbow joint has 
recently been performed on 9 dogs with OA of the elbow and hips (3). This study was 
identical to ours in that force platform gait analysis and range of motion were used to analyze 
joints insertion points treated with ESWT at 0.14 mJ/mm2. 
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Communication with owners at each visit resulted in very diverse accounts of 
subjective improvements among the groups. Five of the 7 owners of the treated dogs were 
very enthusiastic about the treatment and asked if their dog could receive monthly ESWT. 
The owners appreciated the improvement that resulted from the treatment and noticed 
increased activity of their animals. Four of the 5 'control dog' owners had not noticed any 
change before a gradual decrease in activity of their pet. However, when evaluating the 
owner questionnaire, these reported changes did not result in a significant difference between 
groups. 
As a result of these findings, further evaluation of stifle osteoarthritis should take into 
consideration that progression of the disease would cause ground reaction forces to change 
over time. Variability in vertical gait is likely to be related to repeat cycling of joint 
instability, consequent cartilage and meniscal injuries, and eventual fibrosis of the 
retinaculum (1). The dogs in our study were, no doubt, in varying stages of osteoarthritis. 
Regardless of severity of OA, it should be noted that dogs display inter-day variation in the 
production of force plate data. The mechanisms for this variation have been interpreted as 
deriving from external and internal environmental factors. Minor traumas unnoticed by 
owners and researchers, time of day, weather, may also cause inter-day variation in data 
gathered from individual subjects (20). 
The limited number of cases this study indicate that there were clearly potentially 
positive outcomes associated with the treatment. One must consider these data as a pilot 
study to validate the need for additional larger studies. Future studies that evaluate the uses 
of ES WT in canine osteoarthritis cases need to evaluate a larger number of patients that 
include dogs that are not as advanced as the chronic cases included here, include an attempt 
to correlate outcome with radiographic and clinical findings, and to evaluate ways to improve 
treatment such as changes in the treatment protocol. 
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Footnotes 
1 OR6-6-1000, Advanced Medical Technology, Inc, Watertown, MA, USA 
b Mek 92-Tpad Retroflective Photocell, Sircon Controls, Missisauga, Ontario, Canada 
c Sharon software, Inc, Dewitt, MI, USA 
d Sedazine; Fort Dodge Animal Health, Overland Park, KS, USA 
e Torbugesic-SA; Fort Dodge Animal Health, Overland Park, KS, USA 
rRobinul- V; Fort Dodge Animal Health, Overland Park, KS, USA 
g Dormitor; Pfizer Animal Health, New York, NY, USA 
h Y obine; Lloyd Laboratories, Shenendoah, IA, USA 
i Antisedan; Pfizer Animal Health New York, NY, USA 
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Legend of Figures 
Figure 1. The mean(± SEM) peak vertical forces of treated and control groups for each of 
the 5 visits . ESWT was performed on the treatment group on visits 1, 2, and 3. 
Figure 2. The mean(± SEM) stifle joint range of motion of treated and control groups. 
Goniometer analysis of ROM was performed at each of 5 visits. 
Legend of Tables 
Table 1. The pre and post treatment vertical force parameters and range of motion with the 
slope and the within group match pair p value for both the treated and control groups are 
shown. The between group matched pair p values are on the right side of the table. 
Table 2. Subjective analysis gathered from treated and control client questionnaire 
completed at each of five visits. A score of' 1' means that the symptoms are very severe and 
the dog won't attempt or is unsuccessful with the task. A score of ' 7' means no symptoms 
exist and that ability is as good as when the dog was younger. The mean scores and p values 
from the one way analysis of variance are shown. 
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Treated Group Control Group 
Pre- Post- Slope Within Pre- Post- Slope Within Matched Pairs 
Treated Treated (SE) Group Control Control (SE) Group p Value 
Mean Mean (SE) Matched Mean Mean Matched 
(SE) Pairsp (SE) (SE) Pairs p Value 
Value 
Peak 37.33 37.86 0.15 39.85 36.34 -0.49 0.05 0.79 
Vertical (1.0) (1.18) (0.31) 0.67 (0.8) (0.84) (0.36) 
Force (N/s) 
Vertical 13.62 15.3 0.41 12.99 14.79 0.33 0.01 0.66 
Impulse (0.64) (0.72) (0.10) 0.007 (1.38) (1.21) (0.12) 
(N/s(s)) 
Average -0.41 -0.34 0.01 · -0.69 -0.46 0.06 0.12 0.13 
Falling Slope (0.09) (0.04) (0.01) 0.14 (0.09) (0.05) (0.01) 
(N/m*sec) 
Range of 96.43 113.29 3.34 102.2 98.4 -1.26 0.78 0.18 
Motion (5.74) (3.89) (2.35) 0.07 (5.09) (8.3) (2.74) 
(degrees) 
Table 1 
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Parameter Pre-Treated Post-Treated Pre-Control Post- p value . 
Mean (SE) Mean (SE) Mean (SE) Control 
Mean (SE) 
Reluctance to 4.86 (0.40) 5.83 (0.31) 3.6 (0.81) 4.75 (0.63) 0.67 
rise from resting 
Reluctance to 4.8 (0.37) 6.0 (0.41) 3.4 (0.98) 4.5 (0.96) 0.8 
jump off 
sofa/bed 
Reluctance to 4.5 (0.99) 6.0 (0.63) 2.2 (0.73) 5.25 (0.63) 0.4 
jump in car 
Stiffness in 4.0 (0.58) 5.33 (0.42) 4.0 (0.84) 4.5 (0.87) 0.68 
momin_g 
Stiffness all day 4.86 (0.34) 5.5 (0.34) 4.2 (0.8) 4.75 (0.63) 0.32 
Stiffness post 3.07 (0.66) 5.17 (0.54) 2.4 (0.24) 3.5 (0.87) 0.5 
exercise 
Time spent 5.0 (0.49) 5.5 (0.56) 3.0 (0.71) 3.5 (0.65) 0.93 
playing 
Follow family 6.0 (0.31) 6.17(0.31) 5.0 (1.05) 5.5 (1.19) 0.4 
Daily Walk 3.75 (1.03) 4.0 (1.0) 3.4 (0.68) 4.5 (1.32) 0.74 
Comfort Level 4.25 (0.44) 5.0 (0.45) 3.2 (0.66) 4.5 (0.5) 0.92 
Reluctance to 5.29 (0.47) 6.0 (0.26) 4.0 (0.84) 4.25 (0.48) 0.56 
climb stairs 
Table 2 
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CHAPTER 4. FORCE PLATFORM EVALUATION OF ANALGESIA FROM 
FOCUSED EXTRA CORPOREAL SHOCK WA VE THERAPY IN UNILATERAL 
FORELIMB LAMENESS 
Jessica A. Dahlberg, BS; Scott R. McClure, DVM, PhD; Richard B. Evans, PhD; Eric L. 
Reinertson, DVM, MS 
From the Departments of Veterinary Clinical Sciences (Dahlberg, McClure, Reinertson) and 
Veterinary Diagnostic and Production Animal Medicine (Evans), College of Veterinary 
Medicine, Iowa State University, Ames, IA 50011. 
Accepted for publication in the Journal of the American Veterinary Medical Association 
Summary 
Nine horses with chronic unilateral forelimb lameness were included in the study. 
Force plate measurements of peak vertical force (PVF) and vertical impulse (VI) were 
obtained for 3 days to determine baseline data. Local anesthesia was administered to 
eliminate the lameness and PVF on VI measured. Focused extracorporeal shock wave 
therapy was administered to treat the lameness and force platform data was obtained 8 hours 
later (day 0) and daily for 7 days. 
There was a significant increase in PVF and VI on days 0 and 2 post treatment. The PVF 
was similar between day 2 and the post anesthesia measurements. Results show that there is 
a 2 day period of analgesia following ESWT in naturally occurring lameness in horses. 
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Introduction 
The application of focused extracorporeal shock wave therapy for equine 
musculoskeletal diseases has been an area of clinical interest and research in recent years. A 
number of studies have evaluated the effects of ESWT on multiple musculoskeletal diseases 
of the horse (1-6). Two different types of pressure wave generators have been used in the 
horse (7). True focused extracorporeal shock waves (ESWT) meet the definition of a shock 
wave with a rise and fall of pressure in within 1 microsecond and the maximum pressure is at 
a focal point within the tissues (7). These generators are capable of pressures up to 100 MPa. 
Radial pressure wave therapy (RPWT) has the maximum pressure deposited on the surface 
and it dissipates from that point. The pressure waves from the radial generators have much 
lower peak pressures, approximately 7 MPa, similar positive and negative components, and 
longer pulse durations of greater than 4 microseconds (7). 
While the devices create different wave forms, there have been analgesic effects 
reported for both ESWT and RPWT. There have been multiple hypotheses as to the 
mechanism of analgesia including destruction of nerves or nerve receptors, disruption of 
neurotransmitters, and central control of sensory input, but none are truly supported (8-10). 
Some data is available as to the direct effect of ESWT on nerves. Sciatic nerves from frogs 
were repetitively stimulated with ESWT (11). The conclusion was that shock waves do not 
directly affect nerves, but the nerves are affected though the interaction with small gas 
bubbles. This mechanism as shown in vitro may not be applicable in vivo. In a sheep model, 
ESWT did not result in inflammation or disruption of the nerves. However, RPWT created 
significantly more inflammation in the nerves than ESWT or untreated control nerves (12). 
Two separate studies in horses that utilized both ESWT and RPWT and evaluated skin 
sensitivity to electrical stimulation distal to the treatment site that included the palmar nerve 
(12, 13). Following ESWT or RPWT, no analgesia of the nerve was found in either study. 
In another study in horses RPWT slowed sensory nerve conduction velocity of palmar nerves 
up to 35 days after treatment and caused disruption of the myelin sheath (14) 
Neurotransmitters have been investigated as a potential mechanism of analgesia 
following ESWT or RPWT. Depletion of the neurotransmitters CGRP and PGP of nerves in 
rat paws was seen following treatment with 1000 pulses of ESWT at 0.08 mJ/mm2 (15). 
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However, analgesia in a thermal testing mechanism was not present. The reinnervation was 
complete within 2 weeks. In a sheep model, local neurotransmitters, sP and CGRP were not 
found to decrease in concentration following ESWT or RPWT (12). 
Analgesia after shock wave treatment has been reported in humans (a, 8, 16). After 
application of focused ESWT for the treatment of heel spurs in people, there is a bimodal 
analgesic effect. Pain decreases for 3 to 4 days after treatment, which is followed by a 
gradual return of pain that then again decreases as healing progresses. Painful diseases of 
bone and ligament or tendon junctions in humans will result in a rapid decrease in pain 
without radiographic changes (17). In many of these cases, the analgesic effect appears to be 
independent of the healing process (17). 
In the horse, there is some information as to the presence of analgesia following 
therapy. A local cutaneous analgesia was identified for 72 hours following ESWT using an 
electrical stimulus (12). Following RPWT in a thermal stimulation model, no local 
cutaneous analgesia was found (18). In horses with navicular syndrome, no immediate 
analgesia was seen following RPWT (19). 
The importance of the anesthetic effects of ESWT and RSWT are quite evident. The 
risk to both horse and rider when working without full comprehension of pain is significant. 
This concern has resulted in regulations being involved in multiple racing jurisdictions and 
the Federation Equine International. The objective of this study was to evaluate the duration 
of analgesia associated with ESWT in the horse. Our hypothesis is that a single treatment of 
ESWT will result in a decrease in lameness. The objective of the study reported here was to 
determine the short term effect of ESWT on lameness by force platform evaluations. 
Materials and Methods 
Horses - Nine horses with chronic unilateral lameness localized to a forelimb were 
included. To be included the horses had to be in good health other than the diagnosed 
lameness, have a history of lameness for greater than 6 months, and have a lameness grade of 
2 or 3 out of 5 on the AAEP lameness scale (20). They were excluded if there had been an 
injection into the joint within 90 days, surgery on the joint in 180 days or if they had been 
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treated with topical or systemic medications such as non-steroidal-anti-inflammatory drugs, 
glucosamines or other oral products for lameness 14 days prior to starting the study. All 
horses had lameness localized by perineural and or intra-articular anesthesia and 
confirmation of the specific lameness by radiographic evidence. The Iowa State University 
Animal Care and Use Committee approved this study. 
Force platform gait examination - Force platform gait analysis was performed using 
a biomechanical platformb embedded in a 30-m walkway. Three sets ofretroflective 
photocell receptors, were attached 1 meter apart in series and positioned in the walkway, with 
the middle sensor positioned at the middle of the force plate, and were used to determine 
velocity and acceleration over the 2-m measurement regionc. The horses were trotted across 
the platform at a comfortable speed and ground reaction forces for the forelimb and hind 
limb stance phases were recorded for each passd. Passes were repeated until 5 valid 
measurements were obtained for each limb (trial velocity between 1.80 to 2.60 mis; 
acceleration+/- 0.5 m/s2). A trial was considered valid if a forelimb and ipsilateral hind limb 
foot strike were isolated on the force plate consecutively. The first 5 valid passes were used 
for analysis. The ground reaction forces in the vertical direction were normalized for the 
horses' body weight and used for analysis of limb function. The data evaluated were peak 
vertical force (PVF, N/s), vertical impulse (VI, N/s(s)). 
Procedure - Two clinicians not associated with the project independently assigned a 
lameness score prior to enrollment of the horse into the study and on day 7 of the study. 
Force plate data were obtained daily for each horse for 3 days (day-3 to -1) prior to ESWT. 
In addition, following the force platform analysis on the first day (day -3), local anesthesia 
was used to alleviate the lameness and a force platform analysis was completed. On day 0, 
ESWT was done in the morning and the first post treatment force plate analysis was 
completed 7 to 8 hours later. Force plate analysis was repeated daily though day 7. 
ESWT-The horses were lightly sedated with detomidinee at 0.01 mg/kg, 
administered intravenously and were clipped over the area to be treated. Horses diagnosed 
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with navicular syndrome had the frog pared and the foot soaked for 8 hours prior to 
treatment. There were 1000 pulses administered through the frog with a 35 mm focal depth 
at 0.15 mJ/mm2 with a focused shock wave generatol Another 1000 pulses were 
administered from between the heel bulbs at the same energy. For horses with osteoarthritis 
coupling gel was applied and 800 shock waves were divided 4 sites caudolateral, 
dorsolaterally, dorsomedially and caudomedial using a probe with a focal depth of20 mm. 
This was followed by another 800 shockwaves divided into the same locations, at a focal 
depth of 5 mm at an EFD of 0.14 mJ/mm2, for a total of 1600 pulses. The objective was to 
completely treat the circumference of the joint. 
Statistical analysis - Five valid trials for each forelimb were combined for the mean 
at each time point. The 3 baseline measurements were combined for a single average 
baseline value. A matched pairs t-test was performed to compare between baseline, the post 
anesthetic block measurement and post treatment measurements 0 through 7. A within group 
t-test was used to look for a difference between the navicular syndrome and arthritis cases. 
For all analyses, values of P < 0.05 were considered to be significant. 
Results 
The horses included in the study were a median age of 9 years (range 6 to 28 years) 
and had a mean weight of 524.23 kg (441.78 to 639.83 kg). There were 5 geldings and 4 
females. Two American Paint Horses, 3 Thoroughbreds, and 4 Quarter Horses were 
included. Six horses were diagnosed with unilateral navicular syndrome. Lameness was 
localized by palmar digital nerve anesthesia and they all had radiographic changes consistent 
with navicular syndrome. Three horses had degenerative joint disease localized to the distal 
interphalangeal, metacarpophalangeal, and middle carpal joint with intra-articular anesthesia 
and all 3 had radiographic findings consistent with chronic degenerative joint disease. There 
were no complications associated with the ESWT in any cases. 
There was not a significant difference between the navicular syndrome and arthritis 
cases for any of the parameters measured at any time point so all cases were evaluated 
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together. There was no change in lameness score (P = 0.59) from pretreatment (mean= 2.67, 
range 2 to 3) to day 7 (mean= 2.61, range 2 to 3). 
The baseline was significantly different from post anesthesia for PVF (P=0.0062) and 
VI (P=0.0087). There was a significant difference between baseline PVF and PVF on day 0 
(P=0.003) and day 2 (P=0.0156). The PVF after local anesthesia was not significantly 
different (P=0.14) than PVF 2 days after ESWT (Figure 1). The VI was significantly 
increased over baseline on day 0 (P=0.0244) and day 2 (P=0.0232). The VI was significantly 
different from the post anesthesia VI at all time points. 
Discussion 
The objective of the study reported here was to evaluate the short term analgesia 
following ESWT in horses with naturally occurring lameness. In this study the data indicate 
a period of analgesia that peaked on day 2 after treatment. For this study we selected horses 
that were grade 2 to 3 lame. This provided a group of horses with an adequate degree of 
lameness where improvement would be evident. It is possible that more subtle grade 1 
lameness could be eliminated or not affected by ESWT. All of the horses in this study had a 
chronic lameness. The selection criteria were designed to decrease the likelihood of 
spontaneous improvement. This could potentially select cases that may not be as likely to 
respond with short term analgesia. In these cases of navicular syndrome and osteoarthritis, 
adhesions of the deep digital flexor tendon to the navicular bone, osteophytes, cartilage 
erosions or other anatomic changes may make more profound analgesia less likely to occur. 
It is unknown if the response would be similar in an acute lameness. In the osteochondral 
fragment model where ESWT was started on day 14 after the fragment was created, there 
was less lameness and lower protein in the synovial fluid in ESWT treated joints by day 28 
(21). 
There is a documented dose response of ESWT (22 - 24). There appears to be no 
effect at low energy or low pulse number, the desired effect at mid-range levels, and a 
destructive effect at excessively high energy and high pulse numbers. This has been 
documented in multiple studies, both in vitro and in vivo. In vitro the proliferation of human 
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chondrocytes and ovine bone marrow stromal cells were evaluated at EFDs of 0, 0.02 and 
0.06 mJ/mm2 and 0, 500, and 1000 pulses (24). The cells showed a dose and pulse 
dependent proliferative response. When shock waves were evaluated in partial-thickness 
wounds in pigs, lower energy treatment enhanced healing and the tissue had a larger number 
of microvessels (22). Healing was impeded at markedly higher energy and pulse numbers. 
The horses in this study were treated with a generator clinically available to the equine 
practitioner at energy levels and number of pulses typical for the application (1, 21 ). We did 
not investigate how the dose response will affect the post treatment analgesia period. 
The objective of this study was to evaluate the presence and duration of analgesia 
after ESWT rather than the mode of analgesic action. However, it is apparent from this data 
that the maximum analgesia is not immediate. This is shown by the rise in analgesia to the 
peak at day 2 then decreasing. It would be unlikely that destruction of nerves or nerve 
receptors would respond in this fashion. The results of this study were similar to a controlled 
study with ESWT (12). By measuring the subject's response to electrical stimulation, the 
noted study detected a 3 day period of analgesia over the ESWT treatment site of the mid 
cannon bone (12). 
The graphs of the PVF and VI show an increase from baseline to day 2. The day 0 
and day 2 data were significantly different from baseline; however, the day 1 data was not 
statistically different (P=0.07) based on the level of significance set for this study. The data 
shown in the graphs are group means to illustrate the effect seen. The matched pairs t test 
utilized to evaluate the data, had a data point separate from the group resulting in the P value 
being greater than 0.05. However, the data clearly indicate the increase in analgesia from 
day 0 to the peak at day 2. 
In a study with RPWT in horses with navicular syndrome, the force platform 
measurement results were different than reported here (19). The RPWT deposits the energy 
at the surface and it decreases proportional to the square of the distance. This would limit the 
energy that is transmitted to the navicular region in contrast to ESWT where the maximum 
energy is deposited at the focal point of the navicular region. 
The kinematic parameters of PVF and VI presented here have been identified as the 
best mechanisms to reflect lameness severity and subclinical gait abnormalities (25). The 
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post anesthesia PVF and VI were similar to those reported for sound horses (25). The 
baseline PVF (8.19 N/s) and VI (1.8 N/s(s)) were associated with a mean lameness grade of 
2.67 in this study. When comparing our data to the previously published lameness grade of 
2.5, where the PVF and VI were 6.3 N/s and 1.1 N/s(s) respectively, there is some 
discrepancy. This is likely due to the differences in the velocity parameters used. We 
selected a range of 1.8 to 2.6 compared to a velocity of 2.5 to 3 .5 used for the study 
comparing the vertical forces to the lameness grades. Because these horses were evaluated 
consistently throughout the serial exams, the change over time is the important outcome. It is 
important to note that relying solely on vertical force components at one time point can result 
in misleading data (26). For our study we did not do daily subjective lameness grades. The 
sensitivity of the force plate analysis and previously published data indicating the correlation 
of the data to lameness grades did not warrant daily subjective evaluation. 
It can be difficult to interpret the clinical significance of a change of 1 N/s in PVF and 
a change of impulse of 0.14 N/s(s) from baseline to day 2 where analgesia peaked. The fact 
that the day 2 PVF was not significantly different from post anesthesia would indicate that 
this would be of clinical importance. In the study reported here, there was an acute analgesia 
lasting 2 days in these horses with naturally occurring unilateral lameness. This data should 
be considered when exercising horses following ESWT. 
Footnotes 
a. Ogden JA, Ogden DA. Electrohydraulic SWT: bimodal response (abstr), in 
Proceedings. 5th Int Soc Musculoskelet Shockwave Ther 2002:21. 
b. BP600900, Advanced Medical Technology, Inc, Watertown, Massachusetts. 
c. Mek 92-Tpad Retroflective Photocell, Sircon Controls, Missisauga, Ontario, Canada 
d. Acquire v. 7.3, Sharon Software, Inc, Dewitt, Michigan. 
e. Dormosedan, Pfizer Animal Health, Exton, Pennsylvania 
f. Equitron, Sinuwave, Marietta, Georgia. 
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Legend of Figures 
Figure 1. The mean (±SE) peak vertical force (PVF, Fig IA) and vertical impulse (VI, Fig 
1B) are shown for each time point of the study. The highest PVF and VI were obtained 
following local anesthesia to eliminate the lameness. The baseline was the mean of 
measurements obtained over 3 days prior to ESWT. The day O data was obtained 8 hours 
following ESWT and then every 24 hours after that for 7 days. The day O and 2 PVF and VI 
were significantly increased over baseline (*). The post anesthesia and day 2 PVF were not 
significantly different U). 
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CHAPTER 5. GENERAL CONCLUSIONS 
Orthopedic physicians and veterinarians encounter patients with many pathological 
bone and joint conditions for which routine conservative (rest, corticosteroids, medications, 
physical therapy) or surgical treatment may fail. Chronic musculoskeletal disorders include a 
wide variety of degenerative and inflammatory conditions in both the human and domestic 
animal musculoskeletal system. ESWT provides a non-surgical, non-invasive alternative for 
these patients and can theoretically be applied to a number of musculoskeletal disorders. 
The principal effects of ESWT on tissue have been investigated for over a decade. 
Human medicine has adopted ESWT as an acceptable modality to treat numerous 
musculoskeletal diseases. Veterinary medicine began to utilize ESWT after it had become an 
accepted treatment approach in human medicine. Studies have shown analogous results 
among both humans and animals, but further studies in veterinary medicine are required to 
gain the same support seen in human literature to validate it scientifically. 
The primary outcomes evaluated in the treatment of musculoskeletal disorders with 
ESWT are decreased pain and improvement in function. The first paper presented in Chapter 
3 of this manuscript suggests that ESWT is a feasible treatment in dogs with osteoarthritis to 
avoid clinical signs of increasing lameness and decreasing range of motion of the affected 
joint. We were able to show an improvement in lameness after dogs with stifle osteoarthritis 
were treated with ESWT. Although, the improvement in lameness was not statistically 
significant, the control group experienced a significant increase in lameness. Indeed, a larger 
sample size and more uniform stages of arthritis among our subjects would assist in 
achieving statistical significance for many measured variables. This study evaluated the 
outcome, not mechanism ofESWT. Further studies are necessary to investigate the mode of 
actions of ESWT on musculoskeletal disorders. 
The presence of analgesia after ESWT has been documented and numerous 
mechanisms have been proposed. The second paper described in Chapter 4 defines a period 
of analgesia after horses are treated with ESWT. Pain recognition of the horse after ESWT is 
of great importance to both horse and rider. Withdrawal times after ESWT have been 
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enforced at equine competitions but are only based upon subjective opinion and empirical 
data. We were able to objectively analyze the duration of analgesia with force platform 
analysis and found a 2-day period of analgesia after a single treatment ofESWT. 
Our initial experiences evaluating the effects ESWT on osteoarthritis and analgesia 
showed effects in both categories. To date, there are few reliable studies investigating these 
mechanisms and randomized trials are still rare and required. The publications included in 
this thesis contribute to the emerging knowledge about ESWT in veterinary and human 
medicine and set the groundwork for future studies. 
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